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ABSTRACT

Campylobacter is the major bacterial cause of human gastroenteritis in the United
States and other developed countries. Poultry are considered a main source of human
Campylobacter infections. Thus, reduction of Campylobacter load in poultry is
significant in food safety and public health. However, no effective measure is
commercially available to prevent Campylobacter colonization in poultry to date.
Antimicrobial peptides (AMPs) are short and bactericidal peptides widely present in
intestine to limit bacterial infections. Recently, AMPs have been increasingly recognized
as a novel class of antibiotics (peptide antibiotics) to control foodborne pathogens.
Notably, several potent anti-Campylobacter bacteriocins, a group of AMPs produced by
commensal bacteria, dramatically reduced C. jejuni colonization in chickens and are
being directed toward on-farm control of this pathogen to protect public health. As an
important strategy to evade killing by potential peptide antibiotics and by host innate
defense, AMP resistance mechanisms in C. jejuni are critical to understand, but are still
unknown. In this dissertation, molecular basis of Campylobacter resistance to polymyxin
B, the anti-Campylobacter bacteriocins (BCNs), and a chicken host defense AMP
(fowlicidin-1) was comprehensively examined using both in vitro and in vivo systems.
Although polymyxin B has been successfully used as a model peptide to study AMP
resistance in other Gram-negative bacteria, functional genomics examination in this study
suggested that polymyxin B is not a good surrogate to study Campylobacter resistance to
physiologically relevant AMPs. Campylobacter only developed low-level BCN
resistance with low frequency in vitro and in vivo; the acquired BCN resistance was not
vi

stable in Campylobacter. Genomic examination of two BCN resistant mutants using
DNA microarray and random transposon mutagenesis revealed that the multidrug efflux
pump CmeABC contributes to both intrinsic and acquired resistance of Campylobacter to
the BCNs. Random transposon mutagenesis and targeted site-directed mutagenesis
identified four genes (cbrR, tig, cjaB, and cj1583c) involved in Campylobacter resistance
to fowlicidin-1. These genes were also required for optimal colonization of
Campylobacter in chickens. Together, the findings from this dissertation revealed
uniqueness and complexity of AMP resistance in Campylobacter and will enable us to
develop more sustainable peptide antibiotics and novel intervention strategies to prevent
and control Campylobacter infections in humans and animal reservoirs.

Key words: Campylobacter, antimicrobial peptide resistance, polymyxin B, bacteriocins,
fowlicidins
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INTRODUCTION

Campylobacter has emerged as the leading bacterial cause of human
gastroenteritis in the United States and other industrialized countries (Ruiz-Palacios
2007). This pathogenic organism is also associated with Guillain-Bare syndrome, an
acute flaccid paralysis that may lead to respiratory muscle compromise and death. In the
United States, the estimated cases of campylobacteriosis are more than 2 million, which
have resulted in economical and medical costs of 1.5 to 8 billion US dollars each year
(Buzby et al. 1997). Poultry and their products are the major sources for human
Campylobacter infections (Kassenborg et al. 2004). In parallel to its increased
prevalence, Campylobacter has become increasingly resistant to clinical antibiotics,
posing a serious threat to public health (Allos 2001). Therefore, development of effective
intervention strategies is urgently needed to prevent and control Campylobacter
infections in humans and animal reservoirs.
Endogenous antimicrobial peptides (AMPs) belong to the most ancient and
efficient components of host defense. Defensins and cathelicidins are two major groups
of host AMPs that limit bacterial infections at the gastrointestinal mucosal surface (Bulet
et al. 2004; Wehkamp et al. 2007). In addition to their significant role in host innate
defense, AMPs including chicken cathelicidin fowlicidin-1 (F-1) have been increasingly
recognized as a novel class of antibiotics (peptide antibiotics) to control pathogens (Xiao
et al. 2006; Bommineni et al. 2007). Given the wide prevalence and successful
colonization of C. jejuni in intestinal tract, C. jejuni should have acquired mechanisms to
xiii

resist AMPs widely present in the host. However, as an important strategy to evade
killing by innate immunity and by potential peptide antibiotics AMP resistance
mechanisms are still largely unknown in Campylobacter. Availability of this information
will provide insights into the delicate host-pathogen interactions and reveal novel
intervention targets to control Campylobacter infections in humans and animal reservoirs.
Some commensal bacteria also produce defense peptides, called bacteriocins
(BCNs), to inhibit growth of other bacteria and gain survival advantage in specific niche
in intestine (Riley et al. 2002). The natural and low-toxic BCNs have been proposed as
promising candidates for novel antimicrobials (Cotter et al. 2005). Notably, several antiCampylobacter BCNs have been characterized (Stern et al. 2005; Svetoch et al. 2005;
Stern et al. 2006). These BCNs have displayed potent killing effect against
Campylobacter and dramatically reduced C. jejuni colonization in the intestine.
Therefore, these natural anti-Campylobacter BCNs are being directed toward on-farm
control of Campylobacter (Lin 2009). However, several critical issues of BCN
applications (e.g. resistance development and mechanism) need to be addressed for future
regulatory approval and public acceptability of this intervention measure.
Polymyxin B (PM), a peptide antibiotic, has been used as a model peptide to
study AMP resistance in many Gram-negative bacteria (Ernst et al. 2001; Finlay et al.
2004). Gram-negative bacterial pathogens utilize multiple mechanisms to resist killing by
PMs and other AMPs (Groisman et al. 1997; Ernst et al. 1999; Guina et al. 2000; Ernst et
al. 2001; Groisman 2001; Lee et al. 2004; Moon et al. 2009). Inactivation of the genes
responsible for PM resistance usually results in increased susceptibility of bacteria to a
xiv

variety of innate AMPs, leading to the reduced virulence of the mutants in animal model
system (Ernst et al. 2001). Thus, investigation of PM resistance should be highly relevant
to resistance to physiologically relevant AMPs and pathogenesis of Campylobacter.
The main objective of this project is to examine AMP resistance in
Campylobacter using both in vitro and in vivo systems. The following specific objectives
were persued in this dissertation research:
1) To identify and characterize genes involved in C. jejuni resistance to
polymyxin B.
2) To determine the prevalence, development, and molecular mechanisms of BCN
resistance in Campylobacter.
3) To determine the in vivo development and stability of BCN resistance in
Campylobacter using chicken model system.
4) To systemically identify genes required for Campylobacter resistance to
fowlicidin-1, a chicken host defense peptide.
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CHAPTER I

LITERATURE REVIEW

1

BIOCHEMICAL PROPERTIES AND STRUCTURES
Antimicrobial peptides (AMPs), short peptides with length ranging from 15 to 50
amino acid residues, are produced virtually by all classes of lives from prokaryotes to
human and play an important role in innate immunity due to their potent antimicrobial
activities against microorganisms (Bulet et al. 2004; De Smet et al. 2005). Based on the
sequence and structural analysis, more than 900 AMPs have been predicted and
characterized to date. AMPs exert killing effects against many microorganisms including
bacteria, viruses, and fungi. Recently, some AMPs (e.g. defensin, lactoferin, cecropin,
magainin and melitin) were also found to display anticancer function (Hoskin et al.
2008).
AMPs are cationic and amphipathic molecules (Yeaman et al. 2003). Cationic
characteristic is an important feature of AMPs, which could initiate electrostatic
interaction of AMPs with negatively charged phospholipid membrane of bacteria and
many other microorganisms (Shai 1999; Yeaman et al. 2003; Toke 2005). Most AMPs
have high content of positively charged amino acids such as arginine and lysine rather
than negatively charged amino acids such as aspartic and glutamic acids. Thus, the
overall charge of AMPs is usually cationic, ranging from +2 to +9 at physiological pH
(Yeaman et al. 2003; Bulet et al. 2004; Otvos 2005). Hydrophobicity of antimicrobial
peptides is determined by the percentage of hydrophobic residues in peptides (Yeaman et
al. 2003), which facilitates the interaction of AMPs with hydrophobic regions of
microbial cell membrane. Increasing hydrophobicity significantly increases the ability of
AMPs to bind and permeate bacterial membrane (Yeaman et al. 2003). Together, the
2

cationic and amphipathic properties of AMPs are critical for killing microorganisms.
However,

the amphipathicity of AMPs could cause toxicity to host cells whose

membrane is composed of neutral phospholipids (Yeaman et al. 2003). Based on the
sequence and structure analysis, AMPs have been classified into four groups (Oren et al.
1998; Weinberg et al. 1998):
(1) Linear α-helical AMPs. This group contains AMPs with simple linear, helical
structure lacking disulfide bonds. They can be virtually found in many classes of living
organisms including virus, bacteria, insects, fish, and human (Oren et al. 1998; Tossi et
al. 2000). For example, cecropins, ceratotoxins, and metilins, which are produced by
moths, flies, and bees, respectively, all belong to this group (Saito et al. 2005; Brown et
al. 2008). Despite great differences on the origins, length, charge distribution, and
hydrophobicity, the AMPs in this group contain positively charged regions and prone to
adopt alpha helical conformation. Notably, many such AMPs only become alpha helical
when they interact with amphipathic phospholipids of cell membrane (Yeaman et al.
2003).
(2) Linear α-helical peptides without cystein and with high portion of certain
amino acid residues such as proline, arginine and tryptophan (Dathe et al. 1999;
Yeaman et al. 2003). These AMPs with high content of proline, arginine, or triptophan
have distinctive cyclic structure that typically form extended conformation in aqueous
solution and more compact in hydrophobic solvents (McCafferty et al. 1996). Many
proline-rich AMPs have been identified such as apidaecin from honey bee, pyrrocidin
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from insect, drocins from flies, bac-5 and bac-7 from bovine, and buforin II from frog
(Bulet et al. 2004).
(3)

β-sheet AMPs: This group of AMPs is characterized by the β-hairpin

structure containing disulfide linkages (Weinberg et al. 1998; Reddy et al. 2004). Betasheet AMPs can be isolated from a large numbers of different plants, animals and from
various tissues such as trachea, intestine, tongue, plasma, and skin (Weinberg et al. 1998;
Thomma et al. 2002; Higgs et al. 2007). Defensins, the representative of this group found
in mammals, have three subfamilies sharing common genetic origin including αdefensins, β-defensins, and ө-defensins. All of these mammalian defensins are small
molecules (18–45 residues) that are cysteine and arginine-rich, and have a predominantly
β-sheet structure that is stabilized by three intramolecular disulfide bonds (Sugiarto et al.
2004).
(4) Cysteine-rich peptides. This group of AMPs contains several cysteine
residues near C-terminal and N-terminal facilitating intramolecular disulfide bonds
(Weinberg et al. 1998). For example, human neutrophil HNP-1, -2, and -3 from human
granules (Ganz et al. 1985), drosomocin from drosophila, bacternectin from bovine
neutrophill, brevinins and esculetin from frog skin (Ganz et al. 1985; Weinberg et al.
1998) have three to four disulfide bonds making up complex structure containing alpha
and anti-parallel beta sheets (Reddy et al. 2004).

MODES OF ACTION

4

AMPs have very diverse sequence composition, conformation structures, and
biophysical characteristics. The modes of action of AMPs are not fully understood.
However, it has been widely accepted that AMPs exert antimicrobial activities through
their interactions with the target membrane and interfering with the intracellular
components of the microorganisms (Park et al. 1998; Shai 1999; Reddy et al. 2004; Otvos
2005; Brown et al. 2006; Meade et al. 2009).
Bacterial membrane targets. Fundamental differences between the mammalian
cell membrane and bacterial cell membrane are the constituent compositions and
architectures of the cell membrane. The normal mammalian cell membrane lipid bilayer
is composed

of neutrally charged

lipid

such as phosphatidylcholine (PC),

phosphatidylethanolamine (PE), and sphingo myline (SM). However, the lipid bilayers
of bacterial cell membrane consist of positively charged components such as
phosphatidylglycerol (PG), phosphatidylserine (PS), and cardiolipin (Yeaman et al.
2003). The surface peptidoglycan is also negatively charged with the presence of techoic
or terichuronic acids. In addition, Gram-negative bacteria have outer membrane
composed of lipopolysaccharides (LPS) with negatively charged constituents such as
phosphate group. These features make bacterial cell membrane have higher overall
negative charge than normal mammalian cell membrane. Therefore, the negative charge
together with the amphipathic feature of bacterial cell membrane facilitates the direct
interaction between AMPs and bacterial envelope.
AMPs interact with bacterial cell membrane via electrostatic and/or hydrophobic
interactions. Briefly, cationic AMPs contact with negatively charged phosphate lipid
5

group of membrane via electrostatic force. Following this process is the interaction of
hydrophobic domains of AMPs with hydrophobic groups of lipid chains in membrane.
These interactions facilitate the AMP structure transit to favorable conformation, leading
to the membrane pore formation, following by permeation, and transfer of AMPs into the
cells. Three models of bacterial cell membrane pore formation have been proposed
including barrel-stave mechanism, carpet-like mechanism, and toroidal pore mechanism
(Oren et al. 1998; Park et al. 1998; Shai 1999; Yeaman et al. 2003; Bulet et al. 2004;
Sengupta et al. 2008). Although AMPs commonly interact with bacterial cell membrane
without requirement of AMP specific receptor, recent research demonstrated that some
AMPs interact with bacterial cell membrane through specific receptors. For example,
some AMPs, such as nisin, could target on lipid II, the precursor required for membrane
peptidoglycan synthesis during cell division, and cause cell death (Hasper et al. 2004).

Intracellular targets. The membrane perturbation of AMPs has been widely
examined and is a major mechanism of AMP actions. However, there is increasing
evidence to prove that AMPs have intracellular targets (Kragol et al. 2001; Xiong et al.
2002; Yeaman et al. 2003; Otvos 2005; Pujals et al. 2008; Cho et al. 2009). Some AMPs
could inhibit DNA replication. For instance, buforin II directly binds to DNA (Cho et al.
2009). Thrombin-induced palette protein tPMP-1, human neutrophil defensin HNP-1, and
bacterial peptide microcin B17 have been reported to interfere with DNA gyrase, an
essential enzyme for relaxing the DNA scaffold during DNA replication (Xiong et al.
1999; Heddle et al. 2001; Otvos 2005; Cho et al. 2009). Demaseptin, a chiramic peptide,
could inhibit RNA synthesis (Balaban et al. 2004). Several AMPs also interfere with
6

protein translation and functions. For example, tPMP-1 binds to both 30S and 50S
ribosomal subunits while HNP-1 only binds to 50S subunit (Xiong et al. 1999); prolinerich peptides pyrrhocoricin, drocin, and apidaecin could interact with bacterial heat shock
protein DnaK, an important protein responsible for protein folding (Kragol et al. 2001).
Human histatins have high affinity to fungi mitochondrion and inhibit respiration process
(Helmerhorst et al. 1999). However, the mechanisms of translocation of AMPs from
surface to cytoplasm are not fully understood. It is important to note that a single AMP
may have multiple surface as well as intracellular targets.

AVIAN ANTIMICROBIAL PEPTIDES

Recently, a full panel of avian AMPs have been identified and characterized from
chicken, turkey, penguin, and mallard duck (Sugiarto et al. 2004; Lynn et al. 2007).
Based on their sequences and structures, these AMPs fall into two groups, β- sheet and
α-helical known as β-defensins and fowlicidins respectively (van Dijk et al. 2005; Lynn
et al. 2007).
β-defensins are cystein-rich with a triple-stranded β-sheet structure connected by
a loop of β-hairpin and are evolutionary conserved in humans and various animals
(Sugiarto et al. 2004). Avian β-defensins (AvBDs), produced by heterophils and
epithelial cells also called ‘gallinacins’ in chicken, include 14 homologous peptides
encoded by cluster of genes located on chromosome 3 (Xiao et al. 2004; Lynn et al.
2007). Avian heterophil β-defensins include Gal -1, Gal-1α, Gal-2 isolated from chicken;
THP-1, THP-2 isolated from turkey; Osp-1 isolated from ostrich (Sugiarto et al. 2004;
7

Lynn et al. 2007). Avian non-heterophil β-defensins are produced by epithelial cells at
different locations in the body. Chicken Gal-3 and turkey GVP-1 both containing 39
amino acid residues and are produced by tracheal epithelial cells (Zhao et al. 2001).
Penguin sphenicin was isolated from stomach content of penguin (Thouzeau et al. 2003).
Gal-3 was also expressed in large intestine, air sac esophagus, skin, bursa of fabricius,
and kidney (Sugiarto et al. 2004). Different avian β-defensins and nomenclatures are
summarized in Table 1.
Fowlicidin family consists of four members including CTHL-1, CTHL-2, CTHL3 and CTHL-B1 encoded by cluster of genes located on chromosome 2 (van Dijk et al.
2005; Xiao et al. 2006). Phylogenetic analysis demonstrated that CTHL-1, CTHL-2, and
CTHL-3 are expressed by heteotrophil while CTHLB1 is expressed by mucosal epithelial
M cells (van Dijk et al. 2005; Xiao et al. 2006).
Avian AMPs could be constitutively expressed under normal

physiological

conditions to resist microbial infections (Meade et al. 2009). Some chicken AMPs are
expressed at different levels at different locations during early period of embryo
development. Avian β-defensins 9, 10 were highly expressed at day 10 and day 12 in
embryo abdomen while β- defensin 14 was highly expressed in the head of embryo
(Meade et al. 2009). Avian defensins were found to be expressed in liver, intestine, and
reproductive tracts (Silphaduang et al. 2006; Li et al. 2007; van Dijk et al. 2007). The
expression of avian AMPs increases upon microbial infection. The β-defensin 1, 2, 4, 6
and fowlicidins were highly expressed in chicken infected with Salmonella enterica
serova Typhimurium (Akbari et al. 2008).
8

AMPs play an important role in innate and specific immune response. The
antimicrobial activities are more important in avian than mammals because avian
heterophils lack superoxide ion and myeloperoxidase (Penniall et al. 1975; Sugiarto et al.
2004). Avian AMPs have a wide range of antimicrobial activities against Gram-negative,
Gram-positive bacteria, and fungi (Sugiarto et al. 2004). Chicken heterophil β- defensin
Gal-1, Gal-1α, and Gal-2 displayed antimicrobial activities against E. coli and Listeria
monocytogenes; turkey defensins have broader antimicrobial spectrum against various
pathogens including Mycoplasma and fungi (Sugiarto et al. 2004). Antimicrobial
activities of fowlicidins have been well studied. CTHL-1, and 2 display potent and broad
antimicrobial activities against both Gram-negative and Gram-positive bacteria including
those with antibiotic resistance (Xiao et al. 2006). These fowlicidins also have ability to
neutralize bacterial LPS, and consequently reduce inflammation response (Xiao et al.
2006). However, at high concentration, these fowlicidins exert cytotoxicity toward
mammalian erythocytes and epithelial cells (Xiao et al. 2006).

BACTERIOCINS: STRUCTURE AND CLASSIFICATION

Development and spread of antibiotic resistance in bacterial pathogens have been
the driving force for scientists to seek antibiotic alternatives. Great attention has been
focused on bacteriophages, probiotics, and antimicrobial peptides including bacteriocins
(Asaduzzaman et al. 2009; Lin et al. 2009). Bacteriocins (BCNs) are ribosomally
synthesized bacterial proteins or peptides with narrow or broad antimicrobial activity
spectrum against other bacteria. BCNs are produced by both Gram-negative and Gram-
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positive bacteria and up to 99% of bacteria may make at least one BCN for their
microbial defense system (Klaenhammer 1988; Riley et al. 2002).
BCNs have a large degree of structural and biochemical diversity. Although a
large numbers of bacteriocins have been identified and characterized, new BCNs are still
being discovered and documented. Based on the physiochemical properties, BCNs have
been classified into the following classes:
Class I bacteriocin (also named ‘lantibiotics’). Lantibiotics are ribosomally
synthesized peptides containing unusual amino acid lanthionine produced by Grampositive bacteria (Willey et al. 2007). To date, about 50 lantibiotics with average size of
19-38 amino acid residues have been identified and characterized. To synthesize
lantibiotics, the prepeptides of lantibiotic

undergo

extensive posttranslational

modifications (e.g., dehydration of Ser and Thr), followed by the intramolecular addition
of Cys residue onto the modified unsaturated amino acid residues (Willey et al. 2007;
Smith et al. 2008). More than 15 different posttranslational modifications have been
found in lantibiotics. The different posttranslational modifications result in structurally
diverse peptides derived from the same original pre-peptide sequences (Willey et al.
2007).
Class II bacteriocins. Class II BCNs are the heat stable peptides with molecular
weight less than 10 kDa, and do not contain lanthionine as observed in Class I BCNs.
They have not undergone posttranslational modifications (Cotter et al. 2005). Based on
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the structure, antimicrobial activities, and amino acid composition, class II BCNs have
been divided into following three groups.
Class IIa bacteriocins. More than 25 different class IIa BCNs with size ranging
from 37 to 48 amino acid residues have been characterized (Drider et al. 2006). The most
important characteristic of class IIa BCNs is that cysteine residues are usually located at
N-terminal and C-terminal that form disulfide-bridge and stabilize their structure. The
BCNs with higher numbers of disulfide bridges seem to have greater antimicrobial
activities in comparison with those having less disulfide bonds (Eijsink et al. 1998).
Class IIa BCN consists of an N-terminal β-sheet-like domain that is stabilized by the
conserved disulfide bridge and a C-terminal domain consisting of one or two α-helices of
which the central α-helix is usually hydrophilic and the C-terminal

α-helix is

hydrophobic/amphipathic (Fimland et al. 2005). Most of BCNs in this group have
extended C-terminal tail structure containing an additional sulfide bridge to stabilize the
3-D structure. N-terminal β-sheet-like domain contains the conserved YGNGVXaaC βturn motif. This conformation gives N-terminal of class II bacteriocins amphiphilic
characteristics (Fimland et al. 2005). It has been suggested that YGNGVXaaC β-turn
motif is a recognition sequence for membrane receptor which allows correct positioning
of the BCN in the membrane surface (Chen et al. 1997). Previous studies have supported
that the changes in YGNGVXaaC motif could lead to the change of the N-terminal βsheet-like domain, ultimately affecting the antibacterial activities of class IIa BCNs
(Quadri et al. 1997). Furthermore, most positively charged residues are located in the Nterminal of the peptides. Thus, they are of importance for the initiation of electrostatic
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interaction with the cell membrane (Chen et al. 1997). The central hydrophilic or slightly
amphipathic α-helix is believed to have oblique orientation creating 30-600 with cell
interface when class IIa bacteriocin interacts with bacterial membrane. During the
interaction, central hydrophilic α- helix interacts with hydrophilic part of the cell
membrane and spans onto membrane but does not inserts. This interaction facilitates the
insertion of the C-terminal α- helix into the cell membrane (Bhugaloo-Vial et al. 1996).
The C-terminal hydrophobic/amphiphilic α-helix also plays a very important role in class
IIa bactriocin modes of action. It is believed that C-terminal hydrophobic/amphiphilic αhelix is a putative transmembrane helix and inserts into bacterial cell membrane with the
help of upstream oblique α-helix to form “barrel-stave” (Bhugaloo-Vial et al. 1996).
Class IIb bacteriocins are the BCNs containing two peptides that form a
bacteriocin. To date, about 15 two-peptide bacteriocins have been identified and
characterized (Nissen-Meyer et al. 2010). A peptide (15-30 residues) from a two-peptide
bacteriocin displays high antimicrobial activity only when it is combined with a
complementary peptide. It has been proposed that the bacteriocins form a membranepenetrating helix-helix structure involving helix-helix-interacting GxxxG-motifs that are
present in all characterized two peptide bacteriocins. The membrane and two-peptide
bacteriocin interaction results in membrane pore formation that renders the membrane of
sensitive bacteria permeable to a specific group of ions (Nissen-Meyer et al. 2010).
Class IIc bacteriocins consist of BCNs whose N- and C-terminals are covalently
linked, forming cyclic structure. Most BCNs of class IIc BCNs contain D-amino acids
and the mechanisms of action of this bacteriocin group are not been well understood.
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However, there is evidence that the bacteriocins exert killing bacteria via increased
potassium ion efflux (Kawai et al. 2004).
Class III bacteriocins. This group of BCNs also named ‘bacteriolysins’ (Cotter
et al. 2005) are large and heat-labile AMPs with different domains responsible for
different functions such as translocation, receptor binding, and killing activity (Cotter et
al. 2005). Less than 10 class III BCNs have been identified and characterized including
those from non-lactic acid bacteria (Cotter et al. 2005). The mode of action of this group
of BCNs is different from class I and class II BCNs. They display antimicrobial activities
toward sensitive cells by catalyzing cell wall hydrolysis (Cotter et al. 2005). For this
group of BCNs, N-terminal domain is a catalytic domain homologous to endopeptidase
while C-terminal domain is responsible for recognizing the targets (Valdes-Stauber et al.
1994; Lai et al. 2002; Johnsen et al. 2005).

GENETIC ORGANIZATION OF BACTERIOCIN SYNTHESIS

The genes involved in BCN synthesis are generally found in clusters which can be
located on bacterial chromosomes or on plasmids (Peschel et al. 2006; Willey et al. 2007;
Asaduzzaman et al. 2009). The class I BCN producers have a panel of genes involved in
BCN synthesis, which typically consist of genes encoding pre-peptide, posttranslational
modification enzymes, transporters, accessory proteins, immunity proteins, and regulator.
Class II and III BCN producers, however, do not have the enzymes required for
posttranslational modification.
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The structural gene encoding pre-peptide consists of N-terminal leader sequence
and the BCN peptide sequence. The leader sequence contains two glycine residues which
are believed to serve as signal recognition motif for the maturation and membrane
translocation of the peptide across membrane. BCN transport system includes two
distinct proteins: an ABC transporter consisting of 2-3 subunits located on the cell
membrane, and an accessory protein. ABC translocator protein has conserved ATPbinding domain at C-terminal and hydrophobic integral membrane N-terminal domain
which was shown to cleave off the leader peptide sequence at double glycine motif. Cterminal cytosolic domain contains the ATP-binding cassette which, upon binding to
peptide, triggers ATP hydrolysis, consequently changing the ABC conformation leading
to pre-peptide removal and translocation across the cytoplasmic membrane (Havarstein et
al. 1995). It is suggested that the recognition between the N-terminal proteolytic domain
of ABC transporter and the immature BCNs occurs by the interactions between
hydrophobic residues on the amphiphilic α-helix pre-sequence and hydrophobic residues
on or near the catalytic site in the N-terminal proteolytic domain of the ABC transporter
protein (Aucher et al. 2005). Accessory protein bearing a hydrophobic N-terminal region
and a large hydrophilic C-terminal section is postulated to be involved in processing
membrane translocation and helping cleaving off peptide leader sequence (Havarstein et
al. 1995).
The BCN-producers use two distinct mechanisms to protect themselves from
killing by the BCNs produced by themselves, production of immunity protein and
specific ABC transporter. The ABC membrane efflux transporters are encoded by genes
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adjacent to BCN synthesis genes. Different class bacteriocin producers use different
protective strategies. Class I bacteriocin producers use both immunity protein and ABC
type transporter, meanwhile class IIa and IIb producers use only immunity proteins, and
class IIc producers rely only on ABC type transporter (Cotter et al. 2005; Stein et al.
2005). Immunity proteins are highly charged cytosolic proteins associated with cell
membrane (Dayem et al. 1996). Immunity proteins interact with specific membrane
proteins to confer resistance to cognate BCN products (Ennahar et al. 2000; Vincent et al.
2009). Immunity proteins display high specificity towards their BCNs and exert
protection only against their cognate BCNs, or under rare situations, against one or two
other closely related BCNs (Fimland et al. 2002).

REGULATION OF BACTERIOCIN SYNTHESIS

Bacteriocin synthesis has long been proven to be regulated by quorum-sensing
mechanism which includes production of autoinducer and the corresponding twocomponent regulatory systems (Quadri 2002; Sturme et al. 2002). In particular, the
regulation of class II and III BCN synthesis by quorum sensing has been extensively
studied (Quadri 2002; Riley et al. 2002; Stein et al. 2002). The regulatory system is
composed of three gene products, also termed three–component regulatory system which
consists of an autoinducer peptide-pheromone (AIP), a transmembrane histidine kinase
(pheromone receptor), and a cytoplasmic response regulator (Drider et al. 2006). Similar
to the BCN structural genes, the genes encoding for autoinducers have two parts: the
leader sequence and inductive sequence (Ennahar et al. 2000). The processing of
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immature inductive peptide including cleavage of leader sequence and membrane
translocation is similar to the process of BCN maturation and export (Ennahar et al.
2000). Once outside the cell, induction peptides act as autoinducers for quorum sensing
to regulate BCN synthesis. In addition to depending on cell density, production of class II
and III BCNs is affected by temperature, ionic strength, and pH (Leroy et al. 1999;
Fimland et al. 2000). Class I BCN producers do not have specific autoinducer genes in
BCN synthesis cluster. Interestingly, some class I BCNs also could function as an
autoinducer in addition to antibacterial activity. For example, Nisin A has unique
sequences at N- and C-terminal that serve as quorum sensing signal to interact with its
corresponding two-component regulatory systems (Miller et al. 2001; Quadri 2002;
Sturme et al. 2002). However, some evidence suggests that class I bacteriocin producers
also have other autoinducer genes separating from bacteriocin synthesis cluster genes
(Sturme et al. 2002).

APPLICATION OF BACTERIOCINS

BCNs have been widely used in food processing and preservation (Cotter et al.
2005; Drider et al. 2006). Recently, BCNs have been increasingly recognized as novel
antibiotic alternatives to clinical antibiotics to control pathogens (Ennahar et al. 2000;
Drider et al. 2006). Following are brief reviews for the application of BCNs in different
areas.
For decades, BCNs have been used in food processing and preservation. Most
BCNs are produced by food-grade microorganisms such as lactic acid bacteria (LAB). In
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addition, most BCNs are heat and pH stable, low toxicity to eukaryotic cells and resistant
to digestive protease (Cotter et al. 2005; Drider et al. 2006). Thus, application of BCNs in
food processing and preservation have benefits such as extended shelf life of foods,
reducing risks of foodborne pathogen transmission and reducing chemical use as
preservatives (Settanni et al. 2008). Bacteriocins have been applied in food to either
control the microbial succession during fermentation or inhibiting the uncontrolled
growth of bacterial spoilage during storage of both animal and vegetable products
(Aymerich et al. 2002; Settanni et al. 2008). For example, nisin A and Z have been
accepted worldwide as powerful and safe food additives in controlling food spoilage in
almost 50 countries for over 40 years (Asaduzzaman et al. 2009). Inoculation of a
leucocin, a BCN produced by Leuconostoc gelidum, to meat can preserve vacuum-packed
meat up to 8 weeks by inhibiting the growth of Lactobacillus sakei which spoils meat and
generates distinct sulfur odors (Leisner et al. 1996).
Food-borne pathogens are still major problem throughout the world. The leading
human pathogens associated with foods include Campylobacter spp, Salmonella spp, E.
coli spp, and Listeria spp. One potential advantage of BCNs or their producer organisms
is their ability to inhibit the growth or kill foodborne pathogens (Drider et al. 2006). Onfarm control of food borne pathogens is a major concern in the food chain due to the high
probability

of

pathogens

originating

from

farms.

For

example,

human

campylobacateriosis is mostly due the consumption of contaminated poultry meat in
which Campylobacter colonize commensally. Reduction of Campylobacter spp on farms
would significantly reduce Campylobacter in meat, and thus reduce human
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Campylobacter infections (Lin et al. 2009). Several anti-Campylobacter BCNs were
successfully isolated and characterized from chicken commensal bacteria, which include
OR-7 from Lactobacillus salivarius (Stern et al. 2006), E-760 and E50-52 from
Enterococcus faecium (Line et al. 2008; Svetoch et al. 2008), and SRCAM from
Paenibacillus polymyxa (Stern et al. 2005). Animal studies have demonstrated that these
BCNs dramatically reduced C. jejuni colonization in chicken intestine and these
bacteriocins are being developed toward on-farm control of Campylobacter to protect
public health (Stern et al. 2005; Cole et al. 2006; Svetoch et al. 2008; Lin et al. 2009).
BCNs and BCN-producers have been also used to control food borne pathogens
during food processing. For example, supplementation of class IIa bacteriocin producing
LAB to fresh and processed meat resulted in temperature-dependent inhibition of the
growth of Listeria monocytogenesis and Listeria innocua (Hugas et al. 1998). Addition
of purified piscicolin 126 and enterocin CCM4231 to cheese and soy milk during
processing inhibits the growth of L. monocytogenesis (Wan et al. 1997; Laukova et al.
1999). Also addition of piscicolin 126 to ham paste resulted in reduction of L.
monocytogenesis below detectable levels (Jack et al. 1996). Recently, a number of BCNs
isolated from different bacterial strains display antimicrobial activity against L.
monocytogenesis and could be used to control this food borne pathogen in food products
(Drider et al. 2006). BCNs can be used in combination with other methods which will
increase the antimicrobial activity and efficiency of BCNs. These methods include
chemical substances, pulse electric field, heat treatment, hydrostatic pressure, modified
atmosphere packaging, and irradiation (Galvez et al. 2007)

18

The rapid development and spread of multi-drug resistance to traditional
antibiotics are the driving force for seeking alternative methods for infection treatment
and prevention (Davies 1997). In addition, the biggest limitation of conventional
antibiotics is their broad spectrum of activities which kill not only targeted bacteria but
also untargeted microorganisms in various environmental and host niches. Thus, frequent
use of those antibiotics results in intense selection pressure on sensitive microorganisms
in the ecosystem (Walker et al. 2001). The current attempt to solve this problem, perhaps,
is to develop new antibiotics that have narrow spectrum of activity, least likely to
facilitate resistance, and can combat multi-drug resistant bacteria. Given its narrow
killing spectrum and diverse modes of action, BCN is a novel and effective alternative to
conventional antibiotics. The use of BCNs in human and veterinary medicine is still in
the preclinical stages (Breukink et al. 2006). In vivo trials with animal models have
demonstrated the success of bacteriocins in treating infections caused by S. pneumonia,
and multi drug resistant Staphylococcus aureus (Goldstein et al. 1998; Kruszewska et al.
2004). Nisin, lacticin 3147, mersacin, and actagardine have been demonstrated to be
effective against bacterial mastitis, oral decay, enterococcal infection, and septic ulcer
(DelvesBroughton et al. 1996; Goldstein et al. 1998; Galvin et al. 1999).

THE ROLE OF ANTIMICROBIAL PEPTIDES IN INNATE IMMUNITY AND
GASTROINTESTINAL INFECTION

Antimicrobial peptides (AMPs) are a major component of host innate immunity
systems (Mallow et al. 1996; Bals et al. 2003; Bevins 2005; De Smet et al. 2005;
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Hasenstein et al. 2006). Defensins and cathelicidins (α-helical AMPs) are two major
families of AMPs in humans and animals (Wehkamp et al. 2007). Defensins are broadly
present in mammalian epithelial cells and phagocytes with concentrations as high as
millimolar levels. Cathelicidins are present in the granules of phagocytes and mucosal
epithelial cells (Wehkamp, J., J. Schauber, and E. F. Stange. 2007. In the human
intestinal tract both defensins and cathelicidins are important AMPs expressed by the
gastrointestinal epithelium and protect host against pathogens (Wehkamp 2007). αdefensins and β-defensins exert potent killing effect against various pathogens such as E.
coli, Staphylococcus aureus, Salmonella enteritica typhimurium, Pseudomonas
aeruginosa, Listeria monocytogenes ,and fungus Candida albicans (Porter et al. 1997;
Ghosh et al. 2002). The widespread expression of defensins in the GI tract suggests their
important role in the maintenance of a stable microbial population in the intestine. This
could, on the one hand, prevent invasion of host tissues by luminal flora and ingested
pathogenic bacteria, and on the other hand, maintain relative sterility in certain areas of
GI tract (Cunliffe et al. 2004). Mice lacking defensins were found to be sensitive to lethal
infection with S. enteritica serovar Typhimurium, but transgenic mice that expressed
human defensins could resist oral infection with S. enteritica serovar Typhimurium at
dose lethal to nontransgenic animal control (Salzman et al. 2003). Moreover, in wild type
mice the antimicrobial activity was largely neutralized by defensin-specific antibodies,
indicating that defensins were responsible for most of the activity. Taken together, these
experiments provided important evidence for the protective role of defensins in the early
stage of infection. Several studies also demonstrated that defensins take part in adaptive
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immunity by acting as chemo-attractants for dendritic cells (DCs), monocytes, and T cells
(Durr et al. 2002).
Cathelicidins are widely expressed in various tissues including myeloid cells,
mucosal surface of skin, respiratory epithelia, GI tract, reproductive tract, eccrine and
salivary glands (Zanetti 2005). Cathelicidins display antimicrobial activities against many
microorganisms including Gram-negative bacteria

such as P. aeruginosa, S.

typhimurium, E. coli and Gram-positive bacteria such as S. aureus and S. epidermidis
(Smeianov et al. 2000). Cathelicidins-deficient mice developed much larger areas of
subcutaneous infection with Group A Streptococcus than heterozygous or wild type mice
(Nizet et al. 2001). Other effects of cathelicidin (LL-37) to the innate immune response is
the ability to bind and neutralize the biological activities of LPS, a septic shock
component of gram negative bacteria (Larrick et al. 1995). Recruitment of immune cells
to the site of infection is one process in the innate and adaptive defense. Cathelicidins are
chemotactic for neutrophils, monocytes, mast cells, and T-cells. In addition, they induce
degranulation of mast cells, alter transcriptional responses in macrophage, stimulate
wound vascularization and re-epithelialization of the healing skin, and antitumor
activities (Okumura et al. 2004; Zanetti 2004).
Other host AMPs such as histatins and lysozyme that are produced by mammalian
parotid glands also play an important role in innate immunity. Histatins have
antimicrobial activity against pathogenic fungi such as Candida albicans, Cryptococcus
neoformans, and Aspergillus fumigatus (Helmerhorst et al. 1999). Histatins can bind to a
receptor and enter the cell, leading to cell cycle arrest, efflux of ATP out of the cell, and
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release of the reactive oxygen radicals (Kavanagh et al. 2004). Lysozyme displays
bactericidal activity by hydrolyzing β1-4 glycosidic bonds between N-acetyl glucosamine
and N-acetyl muramic acid of Gram-positive bacterial cell wall and subsequently causes
cell death. Lysozyme is active against Enterococcus faecalis and Staphylococcus aureus
(Dommett et al. 2005). Moreover, lysozyme is also able to enhance the phagocytic
activity of both polymorphonuclear leukocytes and macrophages and bind to free LPS
and lipoteichoic acid of Gram-negative and Gram-positive bacteria respectively
(Kokoshis et al. 1978; Ginsburg 2002). PLA2, cytokine CCL20 expressed in GI tract, has
strong antimicrobial activity against a variety of microorganisms such as Salmonella, E.
coli, Listeria, and C. albicans (Beers et al. 2002; Yang et al. 2003). Taken together,
AMPs play indispensible roles in innate immunity in gastrointestinal tracts.

ANTIMICROBIAL PEPTIDE RESISTANCE IN GRAM-NEGATIVE BACTERIA

Bacterial pathogens have co-evolved with host innate defense and developed
means to curtail the effects of endogenous AMPs such as defensins, cathelicidins and
bacteriocins (Riley et al. 2002; Peschel et al. 2006). The best studied AMP resistance
mechanisms in Gram-negative bacteria involve 1) electrostatic repulsion of AMPs by
modification of cell surface, 2) proteolytic cleavage of AMPs, and 3) active extrusion of
AMPs by drug efflux pumps (Guo et al. 1998; Yeaman et al. 2003; Campos et al. 2004).
Other mechanisms, such as capsule production, changes in the composition of lipid fatty
acids in membrane and maintenance of appropriate membrane potential have also been
implicated in AMP resistance (Campos et al. 2004). Gram-negative bacteria capable of

22

surviving exposure to AMPs utilize two distinct strategies: constitutive resistance and
inducible resistance (Guo et al. 1998; Yeaman et al. 2003; Yount et al. 2005). These two
strategies are briefly reviewed below.
Constitutive mechanisms of resistance are defined as intrinsic or inherent
properties of bacteria that confer basal level of AMP resistance and are constitutively
expressed. In general, there are five mechanisms contributing to constitutive resistance to
AMPs: 1) Inherent cell wall composition or architecture. Most AMPs interact with
bacterial cell wall which is composed of glycocalyx or phospholipids. Thus, bacteria
possessing unusual glycocalyx or phospholipid composition inherently may lack
electrostatic affinity or even repel cationic AMPs, leading to significant intrinsic AMP
resistance (Yount et al. 2005). 2) Influence of transmembrane potential. Transmembrane
potential is electrochemical gradient between inner and outer bilayers of the cytoplasmic
membrane, resulting from differing degrees and rates of proton flux across the
membrane. This significant difference in membrane electrochemistry has been postulated
to be crucial in defining selective toxicity of AMPs through self-promoted uptake
mechanism (Hancock 1997). Transmembrane potential or proton motive force of
energized membrane facilitates the interaction with antimicrobial peptides. Thus,
reduction in transmembrane potential may help bacteria resistance to AMPs (Yeaman et
al. 1998). 3) Electrostatic shielding. Capsule, glycocalyx or biofilm of certain bacteria
containing an anionic complex of carbon hydrate and phosphate including anionic acid
alginate plays very important role in adherence of bacteria to the target cells and helping
them to avoid opsonic phagocytes (Campos et al. 2004; Bishop et al. 2008). In vitro study
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showed that the cationic peptides are more antagonized by polyanion alginate (Friedrich
et al. 1999). Capsule of some bacterial pathogens such as P. aeruginosa, E. coli,
Klebsiella has been demonstrated to have electronegative alginate which is thought to
sequester cationic antimicrobial peptides, consequently preclude peptide access to the
bacterial membrane (Chan et al. 2004). 4) Multidrug efflux pumps. There three major
families of multidrug efflux pumps have been characterized in Gram-negative bacteria,
which include the Major Facilator Superfamily (MFS), the ATP-binding cassette (ABC)
superfamily, and the Resistance Nodulation Division (RND) family (Piddock 2006). The
constitutively expressed efflux pumps have been demonstrated to play a role in resistance
to AMPs such as protamine and human β-defensins (Lin et al. 2002; Moskowitz et al.
2004; Eswarappa et al. 2008). 5) Niche-specific resistance. In certain anatomical and
physiological niches, bacteria can resist killing by AMPs due to the expression of
specific components in specific niches (Yeaman et al. 2003). Some bacteria have
potential to exploit specific anatomical settings as a means of circumventing the effect of
antimicrobial peptides. For instance, opportunistic Gram-negative bacterium P.
aruginosa preferentially colonizes tissues such as respiratory airway, the mucosal surface
having abnormal osmotic or ionic strength. The lipid A structures in cystic fibrosis
(airways) clinical isolates that are more resistant to antimicrobial peptides are distinct
from those seen in acute clinical infections and isolates from environments (Ernst et al.
1999). This phenomenon suggests that the anatomical and physiological niches facilitate
AMP resistance.
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With respect to inducible AMP resistance mechanism that is triggered by
environmental signals, modifications of LPS in outer membrane via two-component
regulatory systems (e.g. PhoP/PhoQ) have been identified as major mechanisms to APMs
in Gram-negative bacteria (Guo et al. 1998; Yount et al. 2005). The negatively charged
LPS involves the electrostatic interaction of cell surface with cationic AMPs in Gramnegative bacteria. Thus, Gram-negative bacteria can add covalent modification to LPS
and consequently reduce the negative charge and/or membrane fluidity of LPS and
protect themselves from attacks by AMPs.

AMP resistance mediated by LPS

modifications has been well studied in Salmonella typhimurium (Gunn et al. 1996; Guo et
al. 1998; Guina et al. 2000) and in other bacteria including Escherichia coli (Trent et al.
2001; Yan et al. 2007; Herrera et al. 2010), Pseudomonas aeruginosa (Dorrer et al.
1977; Ernst et al. 1999), Proteus mirabilis (McCoy et al. 2001; Wang et al. 2008),
Bordetella bronchiseptica (Banemann et al. 1998; West et al. 2000). In Salmonella, twocomponent regulatory systems including PhoP/PhoQ and PmrA/PmrB contributed
significantly to LPS modifications and AMP resistance by modulating the transcription
of genes involved in the modification of lipid A, the bioactive component of LPS (Gunn
et al. 1996; Gunn et al. 1998). In response to low extracellular Mg2+ or Ca2+, PhoP/PhoQ
directly activated pagP and ugtL genes for LPS modification (Guina et al. 2000). PagP is
an outer membrane protein essential for addition of palmitate to Salmonella lipid A,
leading to the enhanced resistance of S. typhimurium to α-helical AMPs (Guina et al.
2000). UgtL is an inner membrane protein that promotes the formation of
monophosphorylated lipid A in the LPS and contributes resistance to polymyxin B (PM)
and α-helical AMP magainin (Shi et al. 2004). By mediating activation of the second
25

two-component system PmrA/PmrB under low

Mg2+ conditions, PhoP/PhoQ also

indirectly activated genes required for modification of lipid A with aminoarabinose
(Gunn et al. 1998; Guina et al. 2000) and phosphoethanolamine (Gunn 2001).
Specifically, the pbgP operon and ugd genes were essential for both the biosynthesis and
incorporation of aminoarabinose into lipid A and are required for PM resistance (Lee et
al. 2004). The pmrC gene encoding

a putative aminotransferase mediated

phosphoethanolamine modification of lipid A and confers PM resistance in S.
typhimurium (Lee et al. 2004).
In addition to LPS modification, Gram-negative bacteria also have other inducible
mechanisms to resist AMPs via two-component or other regulatory systems. Direct
degradation of AMPs by proteases is important for α-helical AMP resistance in some
bacteria. Salmonella outer membrane endopeptidase PgtE inactivated a panel of α-helical
but not β-sheet AMPs and inactivation of PgtE resulted in increase in vitro sensitivity of
Salmonella to many α-helical AMPs (Guina et al. 2000). PgtE homologies were found in
outer membrane of E. coli (OmpT), and Yersnia (Pla) (Sugimura et al. 1988; Sodeinde et
al. 1992), suggesting that this is a common AMP resistance mechanism in bacteria.
Expression of E. coli OmpT increased survival of E. coli growth in the presence of
protamine. OmpT degraded protamine at the extracellular facet of the outer membrane
(Yeaman et al. 2003). Strains with deletion of this gene became hyper susceptible to
protamine. Some Gram-negative bacteria can also secrete peptidase to inactivate AMPs.
Secreted metallopeptidases ZmpA and AmpB were found in Burkholderia cenocepacia.
These enzymes were shown to cleave human cathelicidin LL-37 and β-defensin-1,

26

respectively (Kooi et al. 2009). In addition to AMP enzymatic degradation, there also
have been numbers of studies on the role of efflux pumps in inducible AMP resistance.
In Neisseria gonorroeae, efflux pump MtrCDE expression was increased in the presence
of protegrin-1 and human cathelicidin LL -37 (Shafer et al. 1998). Similarly, the efflux
pump RosA/RosB in Yersinia was found to be induced in the presence of AMPs such as
polymyxin B (Bengoechea et al. 2000). Collectively, resistance to AMPs in bacteria is
mediated by membrane potential, modification of bacterial membrane, production of
enzymatic activities, and efflux pumps.
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Table 1. Nomenclature of chicken β-defensins
No.
1
2
3

New gene/protein
name
Avian beta-defensin
1 (AvBD1)
Avian beta-defensin
2 (AvBD2)
Avian beta-defensin
3 (AvBD3)

RefSeq definition
Gallinacin 1
(GAL1)
Gallinacin 2
(GAL2)
Beta-defensin
prepropeptide
(GAL3)
GAL4 (GAL4)

Lynn/Higgs et al.
definition
Gallinacin 1 (GAL1)
Gallinacin 2 (GAL2)
Gallinacin 3 (GAL3)

4

Avian beta-defensin
4 (AvBD4)

5

Avian beta-defensin
5 (AvBD5)

GAL5 (GAL5)

Gallinacin 9
prepropeptide (GAL9)

6

Avian beta-defensin
6 (AvBD6)

GAL6 (GAL6)

Gallinacin 4
prepropeptide (GAL4)

7

Avian beta-defensin
7 (AvBD7)

GAL7 (GAL7)

Gallinacin 5
prepropeptide (GAL5)

8

Avian beta-defensin
8 (AvBD8)

GAL8 (GAL8)

Gallinacin 12
prepropeptide (GAL12)

9

Avian beta-defensin
9 (AvBD9)

GAL9 (GAL9)

Gallinacin 6
prepropeptide (GAL6)

10

Avian beta-defensin
10 (AvBD10)

GAL10 (GAL10)

Gallinacin 8
prepropeptide (GAL8)

11

Avian beta-defensin
11(AvBD11)

GAL11(GAL11)

12

Avian beta-defensin
12(AvBD12)

Beta-defensin 12
(GAL12)

Gallinacin 10
prepropeptide (GAL10

13

Avian beta-defensin
13(AvBD13)

Beta-defensin 13
(GAL13)

Gallinacin 11
prepropeptide (GAL11)

14

Avian beta-defensin
14(AvBD14)

Gallinacin 14
(GAL14)
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Gallinacin 7
prepropeptide (GAL7)

Xiao et al.
definition
Gallinacin 1
(GAL1)
Gallinacin 2
(GAL2)
Gallinacin 3
(GAL3)
Betadefensin 4
(AvBD4)
Betadefensin 5
(AvBD5)
Betadefensin 6
(AvBD6)
Betadefensin 7
(AvBD7)
Betadefensin 8
(AvBD8)
Betadefensin 9
(AvBD9)
Betadefensin 10
(AvBD10)
Betadefensin
11(AvBD11)
Betadefensin
12(AvBD12)
Betadefensin
13(AvBD13)
Betadefensin
14(AvBD14)

CHAPTER II

MECHANISMS OF POLYMYXIN B RESISTANCE IN
CAMPYLOBACTER JEJUNI
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ABSTRACT
Antimicrobial peptides (AMPs) function as critical innate barriers limiting
bacterial infections at the gastrointestinal mucosal surface. Recently, AMPs also became
recognized as a novel class of antibiotics to control pathogens. As an important strategy
to evade killing by host innate immunity and by novel peptide antibiotics, the
mechanisms of AMP resistance in C. jejuni are critical to understand, but are still
unknown. In this study, Polymyxin B (PM), a peptide antibiotic, was used as a model
peptide to study mechanisms of AMP resistance in Campylobacter. Using bioinformatic
and microarrays in conjunction with molecular approaches, we observed that several
lipooligosaccharide (LOS) synthesis genes (galU, waaC, waaF, neuB, and cgtA) were
involved in PM resistance in Campylobacter. Inactivation of GalU also resulted in
significantly reduced colonization ability of C. jejuni in chickens. Examination of the
sequences encoding various two-component regulatory systems in two PM resistant
mutants did not identify any mutations, which is different from what has been observed
in other Gram-negative bacteria. Transcriptome analysis of PM resistant mutant using
microarray showed that Cj0811, which is likely involved in lipid A synthesis, contributed
to PM resistance. However, the identified genes were not involved in resistance of
Campylobacter to physiologically relevant AMPs such as chicken host AMPs and antiCampylobacter bacteriocins (BCNs). Therefore, PM may not be an ideal surrogate to
study Campylobacter resistance to physiologically relevant AMPs. Natural AMPs should
be directly used to identify Campylobacter genes contributing to AMP resistance.
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INTRODUCTION

Campylobacter has emerged as the leading bacterial cause of human
gastroenteritis in the United States and other industrialized countries (Ruiz-Palacios
2007). This pathogenic organism is also associated with Guillain-Bare syndrome, an
acute flaccid paralysis that may lead to respiratory muscle compromise and death. In the
United States, the estimated cases of campylobacteriosis are more than 2 million. Total
economical and medical costs were estimated 1.5 to 8 billion US dollars each year
(Buzby et al. 1997). Poultry and their products are the major sources for human
Campylobacter infections (Kassenborg et al. 2004). In parallel to its increased
prevalence, Campylobacter has become increasingly resistant to clinical antibiotics,
posing a serious threat to public health (Allos 2001). Therefore, development of effective
intervention strategies is urgently needed to prevent and control Campylobacter
infections in humans and animal reservoirs.
Antimicrobial peptides (AMPs) are a major component of host defense and
function as critical innate barriers limiting microbial infections at the gastrointestinal
mucosal surface in animals (Yeaman et al. 2003; De Smet et al. 2005; Brown et al. 2006).
Recently, AMPs also became recognized as a novel class of antibiotics (peptide
antibiotics) and have been proposed as future anti-infective products to control zoonotic
pathogens in the avian intestinal tract. Notably, some chicken commensal bacteriaproduced AMPs, also called “bacteriocins” (BCNs), dramatically reduced C. jejuni
colonization in chickens and turkeys and are being directed toward on-farm control of
this pathogen (Stern et al. 2005; Svetoch et al. 2005; Stern et al. 2006). As an important
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strategy to evade killing by avian innate immunity and by novel peptide antibiotics, the
mechanisms of AMP resistance are still unknown in C. jejuni. Availability of this
information is not only critical to reveal novel virulence determinants contributing to in
vivo survival of C. jejuni but also is important to better depict the modes of AMP action
and facilitate the development of potent peptide antibiotics to reduce C. jejuni load in
poultry. The recent completion of several C. jejuni whole genome sequences allows us to
comprehensively identify genetic loci required for AMP resistance using functional
genomic approaches.
Polymyxin B (PM), an AMP produced by bacterium Paenibacillus polymyxa, has
been widely and successfully used for studying AMP resistance in bacteria including
different enteric pathogens (Ernst et al. 2001; Finlay et al. 2004). Although PM bears
little structural resemblance to the host defense AMPs, inactivation of the genes
responsible for PM resistance usually resulted in increased susceptibility of bacteria to a
variety of innate AMPs, leading to reduce virulence of the mutants in animal model
system (Ernst et al. 2001). Therefore, studying mechanisms of PM resistance in
Campylobacter may reveal novel virulent determinants required for in vivo adaptation of
Campylobacter. Furthermore, PM is easily available compared to most natural AMPs and
is ideal for large-scale functional genomics studies. Thus, investigation of PM resistance
likely reveals genes important for Campylobacter resistance to physiologically relevant
AMPs.
In our recent study, using random transposon mutagenesis, we identified several
genetic loci contributing to PM resistance including GalU, an enzyme involved in LOS
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synthesis (Lin et al. 2009). In this study, we continue to evaluate the role of galU in AMP
resistance and in vivo colonization of Campylobacter in chickens. The contribution of
other LOS synthesis genes (waaC, waaF, neuB, and cgtA) to AMP resistance was also
determined. In addition, several molecular approaches including microarray and sequence
comparison were used to further determine the mechanisms of Campylobacter resistance
to PM and other AMPs.

MATERIALS AND METHODS

Major bacterial strains and growth conditions. Bacterial strains and plasmids
used in this study are listed in Table 2. Campylobacter strains were routinely grown in
Mueller-Hinton (MH) broth (Difco) or on MH agar at 420C under microaerobic
conditions, which was generated by CampyGen Plus (Oxoid) gas pack in an enclosed jar.
When needed antibiotics kanamycin (Kan) or chloramphenicol (Cm) were added into
MH broth or agar to desired concentrations. E. coli strains were grown at 370C in LuriaBertani (LB) medium with shaking and supplemented with 30 μg/ml of Kan or 20 μg/ml
of Cm.
in vitro selection of PMr mutants. The PMr mutants were obtained by single or
stepwise in vitro selection methods. Briefly, to obtain the PMr mutant JL216 (MIC = 64
µg/ml), an overnight culture of C. jejuni 81-176 grown on MH agar plates was harvested
and approximately 1012 cells were spread on MH agar plate containing 128 µg/ml of PM.
The plates were incubated for two days under microaerophilic conditions at 420C. The
resistant mutants were collected and confirmed by MIC test with PM. The spontaneous
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PMr mutant JL148 (MIC = 64 µg/ml) was obtained from stepwise selection. Briefly,
approximately 1012 CFU of C. jejuni 81-176 were spread on MH agar containing 32
µg/ml of PM. The resistant mutants selected after 2 days of incubation were subsequently
used for additional rounds of selection on plates containing increasing concentrations of
PM. One PMr mutant named JL148 (MIC = 64 µg/ml) was obtained from the third step of
selection using plates with 128 µg/ml of PM.
PCR, qRT-PCR and sequence comparison. Key primers used in this study for
PCR and sequencing are listed in Table 3. PCR was performed in a 50 μl mixture
containing each deoxynucleosite triphosphate at a concentration of 200 nM, each primer
at a concentration of 200 nM, 2.0 nM MgCl2, 50 ng of C. jejuni genomic DNA, and 2.5 U
of Platinum Taq DNA polymerase (Invitrogen). PCR products were purified by
QIAquick PCR Purification Kit (Qiagen), when needed, for cloning or sequencing
analysis. Real-time quantitative PCR was performed as described previously (Guo et al.
2008) using gene specific primers (data not shown). Primers for real time qRT-PCR were
designed

using

Primer3

online

interface

(http://frodo.wi.mit.edu/cgi-

bin/primer3/primer3_www.cgi). Each primer was subsequently analyzed with MFold
(http://www.bioinfo.rpi.edu/applications/mfold/old/rna/)

to

avoid

secondary

RNA

structures and hairpin loops. 16S RNA primers were set for internal control. The qRTPCR was performed as described previously (Lin et al. 2005). The relative expression of
different genes in wild type and PM resistant mutant was normalized with 16S RNA gene
amplified from the corresponding sample. Differential expression was determined by
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threshold cycle (CT) method (Guo et al. 2008) and two independent experiments with
triplicates conducted for each independent experiment for each sample.
Antibiotic susceptibility test. The susceptibilities of C. jejuni strains to PM and
other antimicrobials were determined by standard microtiter broth dilution method with
an inoculum of 106 bacterial cells/ml as described previously (Lin et al. 2002). Minimum
inhibitory concentrations (MICs) were determined by the lowest concentration of a
specific antimicrobial showing complete inhibition of bacterial growth after two days of
incubation at 420C. The tested AMPs were purchased from Sigma (St. Louis, MO; PM,
magainin, cecropin A) or kindly provided by Dr. Norman Stern (USDA; bacteriocin OR7 and E-760).
DNA isolation and natural transformation. Chromosomal DNA was isolated
from Campylobacter using the Wizard Genomic Purification Kit (Promega) according to
the manufacturer’s instructions. Biphasic natural transformation method was performed
as described previously (Davis et al. 2008). Briefly, C. jejuni cultures grown overnight on
MH agar plates were collected and re-suspended in MH broth to OD600 of 0.5. Bacterial
suspensions (0.5ml) were transferred to sterilized tubes and incubated at 42oC under
microaerophilic conditions for three hours. One μg DNA of donor strain which carries the
chloramphenicol resistant gene (cm) or kanamyxin resistance gene (kan) marker was
added to culture. After five hour incubation, bacterial cultures were spread on MH agar
containing Cm or Kan to select transformants. The transformants were confirmed by PCR
using specific primers.
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Whole genome microarray analysis. We used microarrays to compare the
transcriptome of wild-type C. jejuni 81-176 with that of PM resistant mutant JL216
(Table 2). The microarray glass slides (C. jejuni OciChipTM) were purchased from
Ocimum Biosolutions (Indiana). The bacterial RNA isolation, cDNA synthesis and
labeling, microarray hybridization, and data collection and analysis were detailed in
previous publication (Guo et al. 2008). Briefly, RNAprotectTM Bacteria Reagent (Qiagen)
was immediately added to mid-log phase C. jejuni culture (OD of approximately 0.12) to
keep the bacterial transcriptome intact. Total RNA was then extracted and purified using
RNeasy Mini Kit (Qiagen). Twelve μg of total RNA was reverse transcribed and
fluorescently labeled with Cy3 or Cy5 (Amersham) using SuperScript Indirect cDNA
labeling System (Invitrogen). Equal volumes of Cy3 and Cy5-labeled cDNA were mixed,
dried under vacuum and then suspended in 120 μl of hybridization buffer (Ocimum
Biosolutions). A second microarray slide was hybridized with dye swap to generate
technical replicates. The experiment was replicated five times using RNA from five
independent experiments. Hybridization slides were scanned at 650 nm for Cy5 and 550
nm for Cy3 using Axon GenePix 4000 Scanner at 10-μm resolution. The fluorescent
signal intensities were collected using GenePix Pro4 software and the data was
normalized with removal of outliers and loess smoothing of ratio-intensities plots for
each array. The data was then analyzed using mixed linear models for each gene,
accounting for array variation, dye swap bias, treatment effects. P-value was adjusted by
a False Discovery Rate of 5%. R-package (version 0.5.12 2003) was used for data
normalization and statistical analysis. For this study, we chose a P value of < 0.05 and a
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change ≥ 2.0-fold as the cutoff for significant differential expression between C. jejuni
81-176 and PM resistant mutant JL216.
Construction of isogenic Cj1506c and Cj0811 mutants. A 1.3-kb fragment was
amplified from JL28 genomic DNA using primers Cj1506c-R and Cj1506c-F (Table 3).
The PCR product was purified and ligated into TOPO TA cloning® vector, resulting in
pCj1506c. A 0.8-kb fragment of chloramphenicol resistant cassette (cm) with an XbaI
restriction site was amplified from plasmid pUOA18 (Wang et al. 1990) using primers
CmXbaI-R and CmXbaI-F (Table 3). The PCR product, which was digested with XbaI
was ligated into pCj1506c, which was also digested with XbaI prior to ligation. The
ligation mix was transformed into E. coli DH5α, and one transformant bearing construct
pcmCj1506c was selected on LB agar containing 20 μg/ml of Cm. The construct
pcmCj1506c containing chloramphenicol resistant cassette was introduced into JL28 by
biphasic natural transformation method. One transformant was selected on MH plus 6
μg/ml of Cm and confirmed by PCR.
The same strategy was used to generate a Cj0811 isogenic mutant of C. jejuni
JL216. Briefly, an approximately 1.2-kb fragment of Cj0811 along with 200-bp of its
upstream and downstream regions was amplified using genomic DNA of JL216 and
primers Cj0811-F and Cj0811-R (Table 3). The PCR product was purified and ligated
into a TOPO TA cloning® vector (Invitrogen) resulting in plasmid pCj0811. The
chloramphenicol resistant cassette (cm) with introduced PflmI restriction sites at two ends
was amplified from pUOA18 (Wang et al. 1990). The PflmI digested cm cassette was
inserted into pCj0811 which was digested by PflmI prior to ligation. One mutant
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construct designated as pcmCj0811 was obtained and used for natural transformation
using JL216 as the recipient strain. One transformant (JL417) bearing cm inserted in
Cj0811 was selected on MH agar plate containing 6 μg/ml of Cm and confirmed by PCR
using primers Cj0811-F and Cj0811-R.
Chicken experiment. One day old chickens (a kind gift from Hubbard Hatchery,
Pikeville, TN) were randomly assigned into four groups (5 chickens per group). All birds
were placed in sanitized wire cages with unlimited access to feed and water. All
antibiotic-free feed was prepared by the feed mill at the Johnson Animal Research and
Teaching Unit, University of TN. Prior to inoculation with C. jejuni strains, all birds were
confirmed to be free of Campylobacter by culture of cloacal swabs and plated on MH
agar containing selective supplements that inhibit majority of intestinal microflora. At
day four of age, chickens in each group were inoculated with one of following 4
individual Campylobacter strains via oral gavage with inoculums of 107 CFU per chick:
wild type C. jejuni 81-176, PMr mutant JL280, isogenic galU mutants JL281 or JL282
(Table 2). Fecal samples were collected at 7 and 11 days post inoculation (DPI) and
plated on MH agar containing selective supplements. Campylobacter colonies were
enumerated after two days of incubation under microaerophilic conditions at 420C. The
detection limit of plating method was approximately 100 CFU/gram feces. The
significant difference in Campylobacter colonization levels (log10 transformed CFU/g of
feces) at each sampling point between groups was calculated using Student’s t test. A Pvalue of <0.01 was considered significant.
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RESULTS

The gene galU is responsible for PM and other AMP resistance in C. jejuni.
In our previous study, galU was observed to be responsible for PM resistance in PMr
mutant JL148. In this study, we further tested sensitivity of galU mutant to AMPs from
various sources. As shown in Table 4, inactivation of the galU also led to increased
sensitivity to other AMPs such as colistin, magainin, cecropin-A, and bacitracin.
Complementation of galU (JL230) fully restored resistance levels back to its parent strain
JL148. Although galU was found contributing to several AMPs, it was not responsible
for resistance to chicken AMPs such as fowlicidin-1 and -2, and bacteriocins OR-7 and
E-760.
LOS required for PM resistance in Campylobacter. We further examined if
other LOS synthesis genes are involved in PM resistance, including neuB, ctgA, waaC,
and waaF. As shown in Table 5, inactivation of these genes in PM resistant strain JL216
resulted in increased susceptibility to PM (8 to 32-fold reductions in MIC).
GalU is essential for colonization of Campylobacter in chickens. Because
mutation in galU resulted in significant truncation of LOS of C. jejuni and led to
increased susceptibility to various AMPs (Lin, 2009), GalU may play an important role in
the in vivo colonization of C. jejuni by mediating AMP resistance. To test this hypothesis,
strains wild type C. jejuni JL242, derivative spontaneous PMr mutant JL280 and their
corresponding isogenic galU mutants were inoculated into four chicken groups. As
shown in Fig 1, wild-type C. jejuni JL242 colonized in 80% of the chickens at day 7 post
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inoculation, and by day 11 post inoculation, all of the chickens were colonized by JL242
with a shedding level of about 105 CFU/gram feces. In contrast, C. jejuni was not
detected throughout the study in any of cloacal swabs collected from the chickens
inoculated with JL280 or galU mutants JL281 and JL282.
Sequence comparison of signal transduction systems between wild type and
PM resistant mutants. Many studies have demonstrated that Gram-negative bacteria can
govern inducible antimicrobial peptide (AMP) resistance via surface modifications that
are controlled by two-component regulatory systems (Groisman et al. 1997; Ernst et al.
2001; Groisman 2001; Cheng et al. 2010; Fernandez et al. 2010). Point mutations
occurring in such two-component systems (e.g. PhoP/PhoQ, PmrA/PmrB) could result in
acquired resistance to PM and other AMPs. We hypothesized that the mutants (JL216 and
JL148) with acquired PM resistance may have mutations in two-component regulatory
systems; identification of such two-component system(s) is critical to study the
regulatory mechanisms of AMP resistance in Campylobacter. According to the C. jejuni
NCTC 11168 genome sequence (Parkhill et al. 2000), twelve putative two-component
regulators and seven two component sensors (histidine kinase) exist. In this study, nine
regulators, five histidine kinases, and six signal transduction systems (Table 6) were PCR
amplified from wild-type 81-176 and its two PM resistant mutants JL148 and JL216
using specific primers (Table 3). The PCR fragments were sequenced and compared
using DNAStar. No sequence difference was found in these regulatory genes between
wild-type 81-176 and its PM resistant derivatives.
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Transcriptional profiling of PM resistant mutant JL216. A microarray
experiment was performed to compare the transcriptome of PM resistant mutant JL216
with that of its parent strain C. jejuni 81-176. The microarray result in conjunction with
qRT-PCR revealed that the gene (Cj0811) encoding putative tetraacyldisaccharide 4`kinase LpxK, which is likely involved in lipid A synthesis, was up-regulated (2 fold) and
two other genes down-regulated Cj0403c (4-fold) and Cj1506c (16-fold) (Table 7). The
Cj1506c and Cj0811 isogenic mutants were constructed by site-targeted mutagenesis.
Only isogenic Cj0811 mutant showed increased sensitivity to PM (2-fold) and
inactivation of Cj1506c did not affect MIC of PM compared with its parent strain (data
not shown).

DISCUSSION
Modifications of LPS in conferring resistance to PM and other AMPs have been
found in many Gram-negative bacteria such as Salmonella, Klebsiella, Proteus miralitis,
and E. coli (Guo et al. 1998; Gunn et al. 2000; Campos et al. 2004; Moon et al. 2009;
Cheng et al. 2010). Unlike other Gram-negative bacteria, Campylobacter only has LOS
(not LPS) and capsule polysaccharide (CPS) on the surface (Karlyshev et al. 2005). The
LOS comprises two main components: the hydrophobic lipid A anchor and an
oligosaccharide consisting of a conserved inner core and a hyper variable outer core
(Golec 2007). LOS plays multiple roles in pathogenesis of Campylobacter including
acting as endotoxin, adherence factor, and a factor that maintains stability of the outer
membrane and protects the cells from environmental stress (Kanipes et al. 2008; Jeon et
al. 2009). The enzymes responsible for LOS production in Campylobacter include GalU,
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WaaC, WaaF, WaaM, WaaV (inner core), LgtF, AgtA, and GalT (outer core) (Kanipes et
al. 2008; Naito et al. 2010). In our study, we demonstrated that LOS production in C.
jejuni is required for PM resistance.
Lipid A core modifications including addition or alteration of fatty acid chains, or
addition of polar groups such as phosphoethanolamine, 4-amino-4-deoxy-L-arabinose,
and/or palmitate can confer resistance to AMPs including PM in many Gram-negative
bacteria (Wang et al. 2010). In our study, inactivation of the gene Cj0811 which encodes
putative tetraacyldisaccharide 4`-kinase (LpxK) responsible for addition of fatty acid
chains to a disaccharide backbone resulted in slightly increased susceptibility to PM and
magainin. However, there were no MIC difference caused by Cj0811 with respect to
chicken cathelicidins (F-1 and F-2), or bacteriocins (OR-7 and E-760) (data not shown).
Recently, it has been reported that addition of a polar group phosphoethanolamine at the
1 or 4-position in the disaccharide backbone of lipid A resulted in increased resistance of
C. jejuni to PM (Cullen et al. 2010). Wosten et al (2010) reported that alteration of the
disaccharide backbone in Campylobacter lead to mildly increased sensitivity to PM and
other AMPs including chicken cathelicidin-1 and colistin (van Mourik et al. 2010).
The gene galU is critical for production of uridine diphosphate (UDP)-glucose, a
sugar precursor required for polysaccharide formation and LOS outer core synthesis in
Campylobacter and other Gram-negative bacteria (Weickert et al. 1993). This study
demonstrated that defects in the outer core of LOS due to GalU mutation significantly in
vivo colonization of Campylobacter in chickens. It is not surprising that the in vitroselected PM resistant mutant JL280 also reduced colonization levels in chickens because
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the mutation(s) which occurred in JL280 may exert pleiotropic effects on the phenotype
of C. jejuni in addition to PM resistance, consequently leading to an overall negative
impact on the colonization ability of the mutant. Similar findings also were observed in
that both an AMP-sensitive PhoP-null mutant and an AMP-resistant mutant with a
mutation in the two-component regulatory system PhoP/PhoQ were avirulent in a mouse
model and displayed pleiotropic mutant phenotypes (Gunn et al. 1996; Groisman 2001).
Our result was also consistent with the recent report that inactivation of genes
contributing to synthesis of either inner core (WaaF) or outer core (LgtF) of LOS
abolished Campylobacter in vivo colonization using a chicken model system (Naito et al.
2010).
Mutations occurring in two-component regulatory systems could result in
acquired resistance to PM as well as AMPs in other bacteria (Roland et al. 1993; Gunn et
al. 1996; Guo et al. 1998). Sequence analysis of multiple two-component regulatory
systems in PM resistant mutants did not reveal any mutations when compared to its wildtype PM-sensitive parent strain, suggesting that Campylobacter may use different
mechanisms to acquire AMP resistance. These sequence analyses were also consistent
with the microarray data comparing the transcriptome of wild type C. jejuni 81-176 and
its derivative PMr mutant JL216. If the mutation occurred in the two-component
regulatory systems, many genes would have been found differentially expressed. In fact,
very small numbers of genes (three genes) were found differently expressed between wild
type and PM resistant mutant from microarray data analysis. Comparative genomics
revealed small differences between C. jejuni 11168 and 81-176 (Pearson et al. 2003), and
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because of the unavailability of microarray glass slides designed specifically for C. jejuni
81-176, we could not rule out the possibility that using C. jejuni 11168-based microarray
glass slides for hybridization of C. jejuni 81-176 may fail to identify the genes that are
not present in C. jejuni 11168.
Despite discovery of genes involved in PM resistance in this study, these genes
are not required for Campylobacter resistance to physiologically relevant AMPs (e.g.
chicken host AMP fowlicidins) and to the anti-Campylobacter BCNs. It is likely that
resistance to PM in Campylobacter is unique, possibly mediated by mutations in the
specific targets of PM. The results from this study suggested that PM is not an ideal
surrogate for studying Campylobacter resistance to physiologically relevant AMPs such
as bacteriocins and fowlicidins. More studies are needed to reveal both common and
unique mechanisms of Campylobacter resistance to natural AMPs such as bacteriocins
and fowlicidins, which are described in following chapters in this dissertation.
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Table 2. Major bacterial strains and plasmids used in this study (Chapter II)
Strains or
plasmids
Strains
JL28
JL148
46B1
JL230
JL216
JL320
JL321
JL322
JL323
JL328
JL329
JL330
JL331
JL317
JL388
JL242
JL281
JL280
JL282
JL417

Description

Sources or references

81-176 human isolate with low motility
81-176 derivative PM resistant mutant obtained
by stepwise selection in vitro, MIC = 64 μg/ml
JL148 derivative, galU::kan
46B1 /pGalU
81-176 derivative, PM resistant mutant obtained
by single step selection in vitro, MIC = 64 μg/ml
81-176 derivative, waaC::cm
81-176 derivative, waaF::cm
81-176 derivative, ctgA::cm
81-176 derivative, neuB::cm
JL216 derivative, neuB::cm
JL216 derivative, cgtA::cm
JL216 derivative, waaC::cm
JL216 derivative, waaF::cm
JL216 derivative, galU::kan
81-176 derivative, Cj1506c::cm
81-176 human isolate, highly motile
JL242 derivative, galU::kan
JL242 derivative spontaneous PMr mutant
JL280 derivative, galU::kan
JL216 derivative, Cj0811::cm

(Black et al. 1988)
(Lin et al. 2009)

PCR cloning vector, Ampr
pGEM-T Easy containing 1.3-kb gene fragment
Cj1506c of JL28
pCj1506c with cm cassette inserted in Cj1506c
pGEM-T Easy containing 1.2-kb gene fragment
Cj0811 of JL216
pCj0811 with cm cassette inserted in Cj0811

Promega
This study

F– 80lacZ M15 (lacZYA-argF)U169 recA1
endA1 hsdR17 (rk–, mk+) phoA supE44 thi-1
gyrA96 relA1 –

Invitrogen

(Lin et al. 2009)
(Lin et al. 2009)
This study
(Kanipes et al. 2006)
(Kanipes et al. 2004)
(Guerry et al. 2002)
(Guerry et al. 2002)
This study
This study
This study
This study
This study
This study
(Black et al. 1988)
This study
This study
(Lin et al. 2009)
This study

Plasmids
pGEM-T
pCj1506c
pcmCj1506c
pCj0811
pcmCj0811
E.coli
DH5α
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This study
This study
This study

Table 3. Key primers used in this study (Chapter II)
Primers

Sequence (3’-5’)a

Target genes

Cj1222c-R
Cj1222c-F
Cj1223c-R
Cj1223c-F
Cj1226c-R
Cj1226c-F
Cj1227c-R
Cj1227c-F
Cj1261-R
Cj1261-F
Cj1262-R
Cj1262-F
Cj0246c-R
Cj0246c-F
Cj1189c-R
Cj1189c-F
Cj1191c-R
Cj1191c-F
Cj1492c-R
Cj1492c-F
Cj0951c-R
Cj0951c-F
Cj1491c-R
Cj1491c-F
Cj0889c-R
Cj0889c-F
Cj0890c-R
Cj0890c-F
Cj0643-R
Cj0643-F
Cj1608-R
Cj1608-F
Cj0355c-R
Cj0355c-F
Cj1262-R
Cj1262-F
Cj0793-R
Cj0793-F
Cj0448c-R
Cj0448c-F
Cj1506c-R
Cj1506c-F
CmXbaI-R
CmXbaI-F
Cj0811-R
Cj0811-R
CmPflmI-R
CmPflmI-F

TGCCAGATATGAGAGGTATG
AAGAGGCAGGGGATATTGCT
TTTTGATACCATAATGCAAAAA
TTGATAAGAATTTTGATACAATGAT
AAAACAAATTTACCCCATCTTCA
GGGTGGAGTGGTAAGTCGTG
CACTAACCCCAGCAAAAATAAAA
TGCGACTTTGCTTGTGCTTA
TCCCTTCTATTTTTAAAAGAACGGATAA
AAAGACTACATAAAAATTTACAAGGAC
GTGCGAGTTTCATACCATCG
CATCGGTCGCTTAAGGGTAA
AAAACCTTTCCGGTTGAAGC
TTTGCAAAAATTGCAGAGG
CAAGATGAGAGAGCTCAAGGTG
AAGCCTTGTTGCTGTTCTGC
TTTTGTAATTCAGTTTGCTTTTTG
TGACACCTAAAACACCGATAACA
TGGCGTTATTGTTTGTTACGG
CCCTCATCTCCATTTTGAGC
GTACTAGCACAACCCGCAAA
GTACTAGCACAACCCGCAAA
TGTTTTATATTTTAAGGCTAAATCAGT
ATGGAAAAGACGGGGCTTG
CCCTCGTTTGCGCTAAAAT
AAGTGTTAGGGGTATTGGCTCTAAA
AACCCAAAAATCAAAGCCAAT
GAGGCGTGTGTATTTGTCCA
GCAATGCGTATCAACAATCC
AAAAATTTCCTTTCTTTTGAAAAC
GCAAGTGCCTAGCAAACCTT
AAGCCACAACAACGGAAAAA
CCGAAGGTGCAAAATTGTTA
TTTTCTTAATAAGGATAGAAACAAATGA
TGAAAAGGTGATAAAGCAAGC
CATCGGTCGATTAAAGGTAA
CGTTTTGGGGTGAAAAGAAA
TGTGAACAGAATTTGCTTTTACTTG
GCTTCATGTAAAAGATGAACTTAGC
GCCTTTGCTTGATTTTGCTT
GGCTGAGGACAAGATAGATTGC
GCAAAAAGACATAGAAGA
TTTTCTAGATGATCGGCGGTGTTCCTTT
TTTTCTAGAGCGCCCTTTAGTTCCTAAT
GCGAATTGCTTTTAGGTTATGG
GCTGTTTTAGGGACGGAAGA
TTTCCATTTTTTGGGCGCCCTTTAGTTC
TTTCCATTTTTTGGTGCTCGGCGGTGTT

Cj1222c

a

Cj1223c
Cj1226c (CprR)
Cj1227c (CprS)
Cj1261c (RacR)
Cj1262c (RacS)
Cj0246c
Cj1189c
Cj1191c
Cj1492c
Cj0951c
Cj1491c
Cj0889c
Cj0890c
Cj0643 (CbrR)
Cj1608
Cj0355c
Cj1262
Cj0793
Cj0448c
Cj1506c
cmr cassette
LpxK
cmr cassette

bold and underlined sequences are enzyme restriction sites
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Table 4. Susceptibilities of C. jejuni JL148, isogenic galU mutant 46B, and
complemented construct JL230 to different AMPs
Antimicrobial
peptides
Polymyxin B
Colistin
Magainin
Cecropin A
Bacitracin
Fowlicidin-1
Fowlicidin-2
OR-7
E-760
a

MIC (µg/ml)
46B1
4
2
16
2
512
4
8
1
1

JL148
64
64
32
4
1,024
4
8
1
1

ND: Not determined
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JL230
64
64
32
4
1,024
NDa
ND
ND
ND

Table 5. LOS required for PM resistance in Campylobacter
Strains Isogenic mutants

Function of inactivated genes

JL216
JL328

N/A
JL216 derivative, neuB::cm

N/A
N-acetylneuraminic acid synthetase

64
2

JL329

JL216 derivative, cgtA::cm

Beta-1,4-N-cetylgalactosaminyltransferase

8

JL330

JL216 derivative, waaC::cm

Lipopolysaccharide heptosyltransferase I

8

JL331

JL216 derivative, waaF::cm

ADP-heptose--LPS heptosyltransferase II

8

JL317

JL216 derivative, galU::kan

UTP-glucose-1-phosphate uridylyltransferase

4

N/A, Not applicable
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MIC
(µg/ml)

Table 6. Putative two-component regulatory and signal transduction systems of C. jejuni
11168 used for sequence comparison
Gene name
Cj1222c
Cj1223c
Cj1226c
Cj1227c
Cj1262
Cj1261
Cj1492c
Cj1491c
Cj0889c
Cj0643
Cj1608
Cj0355c
Cj1191c
Cj0448c
Cj1506c
Cj0246c
Cj1189c
Cj0951c
Cj0793

Putative functions
Two-component sensor histidine kinase (DccS)
Two-component regulator (DccR)
Putative two-component sensor histidine kinase (CprR)
Putative two-component regulator (CprR)
Two-component sensor histidine kinase (RacS)
Two-component regulator (RacR)
Two-component sensor histidine kinase
Putative two-component regulator
Putative sensory transduction histidine kinase
Two-component regulator (CbrR)
Putative two-component regulator
Putative two-component regulator
PAS domain containing signal-transduction sensor protein
Putative MCP-type signal transduction protein
Putative MCP-type signal transduction protein
Putative MCP-domain signal transduction protein
Bipartate energy taxis response protein CetB
Putative MCP-domain signal transduction protein
Signal transduction histidine kinase
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Table 7. Transcriptome profiling of PM resistant mutant JL216
Gene
ID

Function description

Fold change
(microarray)

Cj0811 LpxK; putative tetraacyldisaccharide 4`-kinase
Cj0403c Hypothetical protein
Cj1506c Putative MCP-type signal transduction protein
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1.84
- 2.0
- 4.3

Fold change
(qRT-PCR)
2.1
-4
-16

P-value

0.02
5.10E-06
6.60E-06

Figure 1. GalU is required for chicken colonization. Colonization of C. jejuni JL242, its
derivative PMr mutant JL280, and their isogenic galU mutants JL281 and JL282
respectively in chickens. The shedding levels of Campylobacter in chicken colonized by
C. jejuni at 7 and 11 days postinoculation (DPI). Each data point represents the mean
shedding level of Campylobacter of colonized in chickens (10 chickens) of each group.
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CHAPTER III

PREVALENCE, DEVELOPMENT, AND MOLECULAR MECHANISMS OF
BACTERIOCIN RESISTANCE AMONG CAMPYLOBACTER SPP
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ABSTRACT

Bacteriocins (BCNs) are antimicrobial peptides produced by bacteria with narrow
or broad spectrum of antimicrobial activity.

Recently, several unique anti-

Campylobacter BCNs have been identified in commensal bacteria isolated from chicken
intestine. These BCNs dramatically reduced C. jejuni colonization in poultry and are
being directed toward on-farm control of Campylobacter. However, no information
exists concerning prevalence, development, and mechanisms of BCN resistance in
Campylobacter. In this study, susceptibilities of 137 C. jejuni and 20 C. coli isolates to
the anti-Campylobacter BCNs OR-7 and E-760 were examined. Only one C. coli strain
displayed resistance to the BCNs (MIC = 64 μg/ml) while others were susceptible with
MIC ranging from 0.25 to 4 μg/ml. BCN resistant (BCNr) C. coli mutants also were
obtained by in vitro selection but all of them displayed low-level resistance to the BCNs
(MIC = 8 to 16 μg/ml). The acquired BCN resistance in C. coli could be transferred at
intra- and inter-species levels in Campylobacter by biphasic natural transformation.
Genomic examination of the BCNr mutants using DNA microarray and random
transposon mutagenesis revealed that the multidrug efflux pump CmeABC contributes to
both intrinsic and acquired resistance to the BCNs. Together, this study represents the
first report and a major step forward in understanding BCN resistance in Campylobacter,
which will facilitate the development of effective BCN-based strategies to reduce
Campylobacter load in poultry.
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INTRODUCTION

Campylobacter species including C. jejuni and C. coli are the most common
bacterial causes of human gastroenteritis in the United States (Ruiz-Palacios 2007).
Human Campylobacter illnesses are caused primarily by C. jejuni (~90%) and
secondarily by C. coli (~10%). This group of pathogenic organisms causes watery
diarrhea and/or hemorrhagic colitis in humans and is associated with Guillain-Barre
syndrome, an acute flaccid paralysis that may lead to respiratory muscle compromise and
death (Nachamkin et al. 1998). There are more than two million estimated cases of
human campylobacteriosis in the United States each year, and the annual medical and
productivity costs resulting from Campylobacter infection are estimated at 1.5 to 8.0
billion dollars (Buzby et al. 1997). Poultry, particularly chickens, are considered a major
source of human campylobacteriosis (Kassenborg et al. 2004). Thus, on-farm control of
Campylobacter in poultry would reduce risk of human exposure to this pathogen and
have a significant impact on food safety and public health (Lin 2009). In particular, at the
same time that prevalence of infection is increasing, Campylobacter has become
increasingly resistant to antibiotics, including fluoroquinolones and macrolides, the major
drugs of choice for treating human campylobacteriosis (Luo et al. 2005), which raises an
urgent need for novel strategies to prevent and control Campylobacter colonization in
poultry (Lin 2009).
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To date, three general strategies have been proposed to control Campylobacter in
poultry on the farm, including 1) reduction of environmental exposure (biosecurity
measures); 2) an increase in poultry’s host resistance to reduce Campylobacter carriage in
the gut (e.g. competitive exclusion, vaccination, and host genetic selection); and 3) the
use of antimicrobial alternatives to reduce and even eliminate Campylobacter from
colonized chickens (e.g. bacteriophage therapy (Lin 2009)). Effective implementation of
biosecurity measures relies on a better understanding of risk factors and sources of
Campylobacter for poultry (van Gerwe et al. 2009). Except for biosecurity measures, the
other two general intervention approaches are currently not commercially available and
are still under development. Notably, recent breakthroughs in the discovery and
characterization of potent anti-Campylobacter bacteriocins (BCNs) may lead to an
effective measure for on-farm control of Campylobacter in poultry (Lin 2009). BCNs are
short antimicrobial peptides (AMPs) produced and exported by most bacterial species
examined to date for the apparent purpose of destroying their competitors (Riley et al.
2002). Many BCN-producing bacteria (e.g. lactic acid bacteria) are commensals in the
intestine. Therefore, the intestinal BCN-producing bacteria may achieve competitive
advantage and function as an innate barrier against pathogens in the host. The natural
BCNs have been proposed as promising candidates for novel antimicrobials (Cotter et al.
2005). Several anti-Campylobacter BCNs produced by chicken commensal bacteria, such
as OR-7 from Lactobacillus salivarius (Stern et al. 2006), E-760 and E50-52 from
Enterococcus faecium (Svetoch et al. 2008), and SRCAM from Paenibacillus polymyxa
(Svetoch et al. 2005), have displayed potent killing effect in vitro. Oral administration of
these BCNs dramatically reduced C. jejuni colonization in poultry intestine (5-8 log10
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CFU/gram feces reductions). Thus, these natural anti-Campylobacter BCNs have been
proposed as effective alternatives to therapeutic antibiotics and are being developed for
on-farm control of Campylobacter (Lin 2009).
Although the above anti-Campylobacter BCNs have been demonstrated to be very
effective in reducing C. jejuni colonization in poultry, several critical issues (e.g.
production and resistance development) need to be addressed for future regulatory
approval and public acceptability of this intervention measure. In this study, we examined
prevalence,

development,

and

molecular

mechanisms of BCN resistance

in

Campylobacter using molecular and genomic approaches. Our findings strongly suggest
that there is less resistance development for the anti-Campylobacter BCNs, such as OR-7
and E-760 compared to traditional antibiotics. In addition, microarray and random
transposon mutagenesis studies indicated that the multidrug efflux pump CmeABC
contributes to both intrinsic and acquired resistance of Campylobacter to the BCNs.

MATERIALS AND METHODS

Bacteria strains, plasmids, and growth conditions. The major bacterial strains
and plasmids used in this study are listed in Table 8. Among the 157 strains used for the
prevalence survey in this study, 137 isolates are C. jejuni while 20 isolates are C. coli.
These Campylobacter strains were isolated from different hosts including human (15),
bovine (5), chicken (111), turkey (1), pigs (4), as well as from the environment including
mouse traps (5), bird droppings (5), and lagoons (1). All of these strains were collected
from 16 geographically diverse areas in the United States. These C. jejuni and C. coli
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strains were routinely cultured in Mueller-Hinton (MH) broth (Difco) or on MH agar at
420C under microaerophilic conditions, which was generated by CampyGen Plus (Oxoid)
gas pack in an enclosed jar. When needed, MH media were supplemented with
kanamycin (Kan), chloramphenicol (Cm), or BCNs at desired concentration. E. coli cells
were grown at 370C in Luria-Bertani (LB) medium with shaking and supplemented with
30 μg/ml of Kan or 20 μg/ml of Cm.
Bacteriocins. The BCNs OR-7 and E-760 were purified from L. salivarius NRRL
B-30514 and E. faecium NRRL B-30745, respectively, as described in recent publications
(Stern et al. 2006; Line et al. 2008). These BCNs were dissolved in sterile H2O and
stored at -200C prior to use.
BCN susceptibility test. The susceptibilities of C. jejuni and C. coli isolates to
BCNs OR-7 and E-760 were determined by standard microtiter broth dilution method
with an inoculum of 106 bacterial cells/ml as described previously (Lin et al. 2002).
Minimum inhibitory concentrations (MICs) were determined by the lowest concentration
of specific BCN showing complete inhibition of bacterial growth after two days of
incubation at 42 0C.
in vitro selection of BCNr C. jejuni and C. coli. BCN OR-7 was used as a
selective agent for generating spontaneous BCNr mutants in vitro. Briefly, C. jejuni and
C. coli strains were grown in BCN-free MH broth to late log phase. The cultures were
centrifuged and the pellets were suspended in MH broth to a final concentration of
approximately 1010 cells/ml. The cell suspensions were plated in duplicate on MH agar
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plates containing 4, 8, or 16 μg/ml of OR-7. After two days of incubation, the BCNr
colonies were enumerated and the frequency of emergence of BCN resistance was
calculated, which is the ratio of CFU on BCN containing plates to CFU on BCN-free MH
agar plates. The single-step in vitro-selected BCNr mutants were randomly selected and
used for MIC test together with the corresponding parent strain. The experiment was
repeated twice with triplicate measurements in in independent experiment.
DNA isolation and natural transformation. Chromosomal DNA was isolated
from Campylobacter using the Wizard Genomic Purification Kit (Promega) according to
the manufacturer’s instructions. Natural transformation (biphasic method) was performed
as described previously (Davis et al. 2008). The natural transformation efficiency was
expressed as transformants per μg DNA per recipient CFU.
Whole genome microarray analysis.

We used microarrays to compare the

transcriptome of wild-type C. jejuni NCTC 11168 with its BCNr derivative JL341 (OR-7
MIC = 8 μg/ml) (Table 8). The microarray glass slides (C. jejuni OciChipTM) were
purchased from Ocimum Biosolutions (Indiana). The bacterial RNA isolation, cDNA
synthesis and labeling, microarray hybridization, and data collection and analysis were
detailed in our previous publication (Guo et al. 2008). The hybridization experiments
were repeated five times (biological replicate, n = 5) by using total RNA isolated from
five independent experiments. In this study, we chose a P value of < 0.05 and a change ≥
2.0-fold as the cutoff value for significant differential expression between C. jejuni
NCTC11168 and its derivative BCNr mutant JL341.
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in vivo random transposon mutagenesis. The BCNr C. jejuni JL358, a 81-176
derivative (Table 8), was subjected to in vivo transposon mutagenesis using EZ::Tn5™
<KAN-2> Transposome (Epicentre) as detailed in our previous publication (Lin 2009).
Briefly, one microlitter of EZ::Tn5™<KAN-2> Transposome was used to electroporate
C. jejuni JL358 competent cells. The Kanr transformants were individually picked and
inoculated in 96-well microplates. Following 2 days of incubation, cultures of mutants
were replicated into microtiter plates containing 4 μg/ml of OR-7 (4-fold reduction of
MIC of parent strain). Those mutants that could not grow in OR-7-containing medium
were selected from initial plates and subjected to second screening to confirm increased
sensitivities of the mutants to OR-7. To confirm specific genetic associated with the
transposome insertion and the increased susceptibility of each mutant to BCN,
backcrossing of the transposon mutations into the parent strain was performed using
natural transformation (Davis et al. 2008). The MICs of BCN for the backcrossed
mutants were determined together with parent strain C. jejuni JL358. Specific transposon
insertion site of each mutant was determined by direct sequencing of the genomic DNA
(Lin et al. 2009). Sequence analysis was performed using DNAStar software package.
PCR and Real-time qRT-PCR. Key PCR primers used in this study were listed in
Table 9. PCR was performed in a 50 μl mixture containing each deoxynucleotide
triphosphate at a concentration of 200 nM, each primer at a concentration of 200 nM, 2.0
nM MgCl2, 50ng of C. jejuni genomic DNA, and 2.5 U of Platinum Taq DNA
polymerase (Invitrogen). Real-time quantitative RT-PCR was performed as described
previously (Guo et al. 2008) using gene specific primers.
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Isogenic mutants construction and complementation in trans. To construct
isogenic Cj0035c (a putative efflux pump gene) mutant of JL341, genomic DNA of
Cj0035c isogenic mutant of 81-176 (Ge et al. 2005) (Table 8) was extracted and used for
natural transformation with JL341 as a host strain, creating mutant JL377 with insertional
inactivation in Cj0035c.
Isogenic Cj1125c and Cj1687 mutants of JL341 were constructed by insertional
mutagenesis as described in a previous publication (Lin et al. 2005). Briefly, to construct
Cj1125c isogenic mutant of JL341, an approximately 1.7-kb fragment was PCR
amplified from genomic DNA of JL341 using primer pairs of Cj1125cF and Cj1125cR
(Table 9). The PCR product was cloned into pGEM T-easy vector (Promega), resulting in
construct pCj1125c. The chloramphenicol (cm) resistance gene cassette was PCR
amplified from plasmid pUOA18 (Wang et al. 1990) using pfu polymerase (Stratagene)
and primers CmAfeI-F and CmAfeI-R (Table 9). The resulting blunt-ended PCR product
was purified and ligated into pCj1125c vector, which was digested with SwaI prior to
ligation, to generate mutant construct pcmCj1125c. The construct pcmCj1125c, which
serves as a suicide vector, was introduced into JL341 by natural transformation (Van
Vliet et al. 1998). One transformant designated as JL416 was selected on MH agar plate
containing 5 μg/mL of chloramphenicol and the insertion of Cm-resistant cassette was
confirmed by PCR using the specific primers Cj1125cF and Cj1125cR (Table 9).
Similarly, to construct the isogenic Cj1687 mutant of JL341, primers Cj1687-F and
Cj1687-R (Table 9) were used to amplify a 2.0-kb fragment from genomic DNA of
JL341 using Taq polymerase. The PCR product was cloned into a pGEM T-easy vector,
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resulting in the pCj1687 plasmid. The plasmid was then digested by SwaI and ligated to
the PCR product of the Cm-resistant gene cassette as described above, generating
plasmid pcmCj1687. The pcmCj1687 served as a suicide vector to generate an isogenic
Cj1687 mutant in the JL341 background as described above. The Cj1687 mutation in
JL372 was confirmed by PCR using the specific primers Cj1687-F and Cj1687-R (Table
9). A similar site-directed approach was used to create isogenic Cj0630c (DNA
polymerase III, delta subunit) and Cj1116c (a putative membrane bound zinc
metallopeptidase) mutants of JL341.
To complement perR mutation in K15A2, an 81-176 derivative obtained by
random transposon mutagenesis, the complete perR gene together with its 200 -bp
upstream and 100 -bp downstream regions was amplified using PerRF and PerRR
primers (Table 9) in conjunction with Pfu polymerase (Stratagene). The blunt -ended
PCR product was purified and ligated to the SmaI–digested shuttle vector pRY111 (Yao
et al. 1993). The ligation mixture was then introduced into E.coli DH5α, creating
construct JL402. The pPerR plasmid from JL402 was transferred into K15A2 by
triparental conjugation using DH5α/pRK2013 as a helper strain (Akiba et al. 2006). The
complemented strain JL412 was tested for BCN susceptibility together with other related
strains. To complement the cmeB mutation in JL360 (JL341 background), the plasmid
pCME bearing cmeABC operon (Lin et al. 2003) was extracted and transferred into JL360
by natural transformation, creating complemented strain JL424.
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RESULTS

Prevalence of BCN resistance in C. jejuni and C. coli isolates from various
source. Total of 137 C. jejuni and 20 C. coli isolates were subjected to susceptibility test
for BCN OR-7 and E-760. As shown in Fig 2, all C. jejuni isolates were susceptible to
both OR-7 and E-760 with MICs ranging from 0.25 to 1.0 μg/ml. C. coli appeared to
display higher intrinsic BCN resistance than C. jejuni with majority of C. coli showing
MIC ≥ 1 μg/ml. Only one C. coli human isolate, designated as JL106, was resistant to
both OR-7 and E-760 with MIC of 64 μg/ml.
Frequency of emergence of BCNr resistant Campylobacter in vitro. Three C.
jejuni strains (NCTC 11168, 81-176, S3B) and two C. coli isolates (JL20, JL25) that
displayed the same MIC of BCN OR-7 (0.5 μg/ml) were chosen for examination of
frequency of in vitro emergence of BCN resistance. As shown in Table 10, BCNr mutants
were not obtained using C. jejuni strains under the tested selection pressures. In contrast,
C. coli strains displayed higher frequencies of emergence of BCN resistance (1.5x10-8 to
8.7x10-7) in the presence of different concentrations of OR-7 by a single-step selection;
the MICs of selected BCNr mutants ranged from 8 to 32 μg/ml.
The acquired BCN resistance could be transferred at intra- and inter-species
levels in Campylobacter. C. jejuni and C. coli are well-known for the exceptional ability
to acquire exogenous DNA by natural transformation, which is considered a major
mechanism mediating horizontal transfer of antibiotic resistance in Campylobacter. Thus,
we examined if natural transformation contributes to horizontal transfer of BCN
64

resistance in Campylobacter. Genomic DNA of C. coli JL106 (clinical isolate, MIC = 64
μg/ml) and JL349 (obtained from above one-step selection in vitro, MIC = 32 μg/ml)
were extracted and transferred into several C. jejuni and C. coli strains by natural
transformation. As shown in Table 11, the acquired BCN resistance in C. coli JL349
could be transformed to C. coli isolates such as JL20 and JL25 with transformation
frequency about 4x10-7 CFU/μg DNA/recipient cell. Interestingly, the BCN resistance of
JL106 and JL349 also could be easily transferred into different species such as C. jejuni
81-176 and NCTC 11168 with transformation with frequency of 10-8 CFU/μg
DNA/recipient cell. The MICs of BCN for the selected BCNr transformants were up to16
μg/ml (Table 11).
Transcriptional profiling of BCNr mutant JL341. DNA microarray analysis
was performed to compare the transcriptome of the BCNr mutant JL341 to that of its
parent strain NCTC 11168. The microarray analysis revealed that 9 genes were upregulated and 10 genes were down-regulated in BCNr mutant JL341 (Table 12). Since upregulation of some genes such as those involved in LPS modification and peptide
degradation is a common mechanism used by enteric pathogens to confer resistance to
AMPs (Yeaman et al. 2003), the up-regulated genes from this microarray analysis are of
particular concern, which include those encoding multidrug efflux pump CmeABC,
putative drug efflux pump Cj1687 and Cj0035c belonging to a major facilitator super
family, putative membrane bound zinc metallopeptidase Cj1125c, galactosyltransferase
PglA, and a putative DNA polymerase III Cj0630c (Table 12). Up-regulation of these
genes was also confirmed by qRT-PCR using specific primers as described previously
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(Guo et al. 2008) (data not shown). The overexpression of CmeABC in JL341 was further
confirmed by a β-galactosidase promoter fusion assay and immunoblotting using specific
blotting antibodies against CmeB and CmeC as described in our previous publication
(Lin et al. 2002) (data not shown).
The isogenic cmeB, Cj0035c, Cj1125c, and Cj1687 mutants of JL341 were
obtained using natural transformation or site-directed mutagenesis.

However, our

extensive efforts to construct isogenic Cj0630c (DNA polymerase III) and Cj1116c
(membrane Zn metallopeptidase) mutants of JL341 were unsuccessful, probably due to
the essential role of these gene products in Campylobacter growth. Except for the cmeB
mutant, none of the generated isogenic mutants (Cj0035c, Cj1125c, and Cj1687)
displayed increased susceptibilities to OR-7. Inactivation of cmeB in JL341 led to 4-fold
MIC reduction for BCN OR-7 (Table 13). Complementation of the cmeB mutant with
pCME plasmid fully restored MIC back to the level of the parent strain (Table 13). To
test if CmeABC contributes to intrinsic resistance of C. jejuni NCTC 11168 to BCN, the
isogenic cmeB mutant was compared to wild-type strain for susceptibility to OR-7. As
shown in Table 13, inactivation of CmeB in wild-type strain also significantly increased
susceptibility of the mutant (JL199) to OR-7. To determine whether the BCN resistance
in JL341 is partly attributed to the overexpression of CmeABC, the cmeR mutant of
11168, which overexpresses CmeABC (Lin et al. 2005), was also subjected to MIC test.
Compared to its parent strain, overexpression of CmeABC in JL4 due to cmeR mutation
led to slight but consistent increase in the MIC of BCN (1 μg/ml) (Table 13).
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Identification of genes contributing to BCN resistance by random transposon
mutagenesis. A complementary genomic approach to microarray, random transposon
mutagenesis, was used to identify genes involved in BCN resistance in this study. A
library containing 2496 Kanr mutants were generated for screening mutants with an
increased susceptibility to BCN. Six mutants displaying higher susceptibility to BCN
OR-7 than parent strain JL358 were identified (Table 14). Backcrossing of the transposon
mutations into the parent strain by natural transformation further confirmed that the
BCN-sensitive phenotype in each mutant was linked to the gene with a specific
transposon insertion. Direct sequencing of the mutant genomic DNA using transposonspecific primers (Lin et al. 2009) revealed a specific transposon insertion site in each
mutant (Table 14). All the transposon insertions were in coding regions of corresponding
genes. Five of the six mutants had transposons inserted in different sites of the genes
encoding the multidrug efflux pump CmeABC, which has been characterized in our
previous study (Lin et al. 2002). This finding clearly indicated that CmeABC is involved
in acquired BCN resistance in JL358. However, the expression level of CmeABC in
JL358 is comparable to its BCNs parent strain 81-176 as demonstrated by
immunoblotting and LacZ-promoter fusion assay (data not shown). Similar to the finding
in NCTC 11168 (Table 13), inactivation of CmeABC in 81-176 also led to increased
susceptibility to OR-7 (4-fold MIC reductions) (data not shown).
The remaining mutant K15A2 has a transposon insertion in perR, a gene encoding
the Fur family regulator. Complementation of perR mutation in K15A10 (construct
JL412) partially restored BCN resistance to 8 μg/ml for OR-7. In addition, inactivation of
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PerR in wild type C. jejuni 81-176 resulted in increased susceptibility to OR-7 (2-fold
MIC reduction), indicating that PerR is also involved in intrinsic resistance to BCN.

DISCUSSION

The comprehensive survey in this study using Campylobacter strains from various
origins and geographically diverse regions provides more compelling evidence
demonstrating the potent killing activity of BCNs OR-7 and E-760 against
Campylobacter, which has been shown in previous publications (Svetoch et al. 2005;
Svetoch et al. 2008). The survey also clearly indicated that BCN Campylobacter is rarely
detected in clinical and environmental isolates, suggesting that Campylobacter has
difficulty developing BCN resistance in hosts even if Campylobacter may frequently
encounter various BCNs produced by commensals in the intestine (Svetoch et al. 2005;
Svetoch et al. 2008). The finding from this survey is consistent with the examination of in
vitro emergence of BCNr Campylobacter described in this study (Table 10), in which no
BCNr C. jejuni mutants were selected under selection pressure while only C. coli mutants
could develop BCN resistance in vitro with all mutants only displaying low-level
resistance to BCN. Although it is still unknown why C. coli develops BCN resistance
more easily than C. jejuni, our findings strongly suggest that there is less in the way of
resistance development for the anti-Campylobacter BCNs, such as OR-7 and E-760.
These findings support a recent theory that bacteria have not developed highly effective
mechanisms to resist BCNs and other endogenous AMPs during evolution, which is
likely due to multiple activities of natural AMPs (Peschel et al. 2006). The best studied
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BCN is nisin which is ribosomally produced by Lactococcus lactic. Nisin exerts
bactericidal effects via at least two modes of action: targeting the membrane-bound cell
wall precursor lipid II, consequently resulting in inhibition of peptidoglycan synthesis,
and membrane pore formation resulting in membrane damage and depolarization (Hasper
et al. 2006). Resistance to nisin has been reported in some bacteria (Margolles et al. 2006;
Sun et al. 2009); however, high levels of nisin resistance in bacteria were not observed
in bacteria eventhough it has been used as a food preservative for a half century
(Enserink 1999). It has been also reported that the acquired bacterial resistance to BCNs,
such as pediocin PA-1 and nisin A, is unstable and has associated with a fitness cost
(Gravesen et al. 2002). The stability of the acquired resistance to anti-Campylobacter
BCNs in Campylobacter is still unknown and needs to be examined in future studies.
AMPs including various BCNs have been considered potential natural ‘peptide
antibiotics’ to combat bacterial infections (Hancock 1997; Ennahar et al. 2000; Cotter et
al. 2005; Asaduzzaman et al. 2009). Elucidating the underlying mechanisms of AMP
resistance in bacteria could help us to develop ‘smarter’ antibiotics (Peschel et al. 2006).
Therefore, in this study, we also determined genetic loci involved in BCN resistance in
Campylobacter using complementary genomic approaches. Both microarray and random
transposon mutagenesis demonstrated the role of the multidrug efflux pump CmeABC in
resistance of Campylobacter to BCN OR-7. Active extrusion of antimicrobials by
multidrug resistant (MDR) efflux pumps plays vital roles in antimicrobial resistance in
many Gram-negative bacteria (Poole 2000). It has been observed that MDR efflux pumps
are also involved in AMP resistance in several bacteria (Yeaman et al. 2003; Tzeng et al.
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2005; Otto 2009). The best studied bacterium is Neisseria gonorrhoeae whose multidrug
efflux pump mtrCDE contributes to both intrinsic and acquired AMP resistance;
overexpression of MtrCDE mildly increased resistance to human AMPs (2 to 4 fold
increase in MIC) (Shafer et al. 1998). In Campylobacter, the CmeABC MDR efflux
pump contributes to resistance to various antimicrobials, including both structurally
diverse antibiotics and natural antimicrobials present in the intestine, such as bile salts
(Lin et al. 2002; Lin et al. 2003; Yan et al. 2006). In this study, we observed that
CmeABC also contributes to both intrinsic and acquired BCN resistance in
Campylobacter. Notably, the findings from this study indicated that involvement of
CmeABC in BCN resistance does not require overexpression of CmeABC although
overexpression of CmeABC could lead to increased BCN resistance. Together, this study
provides further evidence explaining why CmeABC is essential for Campylobacter
colonization in the intestine (24) and further highlighting the multi-function nature of
CmeABC and critical role of CmeABC in Campylobacter pathobiology.
Although CmeABC plays an important role in BCN resistance, inactivation of
CmeABC alone in the BCNr strain JL360 did not lead to a susceptibility level comparable
to its parent strain JL241 (Table 13), strongly suggesting that other factors work together
with CmeABC to contribute to the acquired BCN resistance observed in JL360. Based
on microarray work in this study, several up-regulated genes are of particular interest. In
addition to the putative efflux transporters Cj1687 and Cj0035c, Cj1116c, a putative
peptidase, may involve proteolytic cleavage of BCNs because degradation of AMPs by
protease is one of mechanisms used by bacteria to resist endogenous AMPs (Yeaman et

70

al. 2003). In Salmonella, the membrane protease PgtE, which is regulated by the two
component regulatory system PhoP/PhoQ, is responsible for degrading cationic AMPs
(Guina et al. 2000). The zinc-dependent membrane metalloprotease ZmpA and ZmpB in
B. ennocepacia degrade antimicrobial peptides protamin and human cathelicidin LL-37
as well as other alpha helical cationic AMPs (Kooi et al. 2009). The PglA (Cj1125c) is a
galactosyltransferase that is involved in N-linked protein glycosylation, a unique surface
carbohydrate modification mechanism that was observed in C. jejuni (Linton et al. 2005);
such surface modification may be required for BCN resistance in Campylobacter. In this
study, we have successfully obtained mutants with mutations in most of these interested
genes. However, none of these mutants displayed increased susceptibilities to BCN
compared to their parent strain JL341. We were not able to generate a mutation in
Cj1116c, strongly suggesting that Cj1116c is an essential gene for Campylobacter
physiology. Additional work, such as production and purification of recombinant
Cj1116c, are needed to determine whether Cj1116c could function as a peptidase to
degrade the anti-Campylobacter BCNs.
Random transposon mutagenesis also identified another gene perR that is
involved in BCN resistance. PerR is a transcriptional regulator controlling transcription
of genes encoding oxidative stress resistance proteins (such as catalase KatA, superoxide
dismutase SodB, and alkyl-hydroxyperoxidase AhpC) (Palyada et al. 2009).
Transcriptional profiling analysis of an isogenic perR mutant identified 104 genes that
belong to the PerR regulon (Palyada et al. 2009). PerR activates several genes encoding
proteins responsible for capsule biosynthesis, which include acetyl-CoA carboxylase
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AccA, 3-oxoacyl-synthase FabH, and fatty acid/phospholipid synthesis protein PlsX
(Palyada et al. 2009). Thus, inactivation of perR in BCNr JL358 may affect capsule
synthesis and such surface remodeling may increase the susceptibility of JL358 to the
BCN OR-7. This speculation needs to be examined in the future.
The results obtained from this study provide helpful information for risk
assessment of on-farm control of Campylobacter using anti-Campylobacter BCNs, and
represent the first and major step forward in understanding the genetic mechanisms of
Campylobacter resistance to BCNs. We have observed that Campylobacter can develop
low-level BCN resistance in vitro. Clinical survey also suggests that Campylobacter may
develop BCN resistance at very low frequency in the host. However, it is unknown if
higher selection pressure (e.g. therapeutic usage of bacteriocins) will promote emergence
of BCNr Campylobacter mutants in vivo. If so, can Campylobacter develop high-level
bacteriocin resistance in response to therapeutic treatment with BCN? In addition, it is
unclear if the BCNr Campylobacter can persist in the absence of selection pressure. To
obtain solid answers to these questions, multiple laboratory experiments using chickens
should be performed to examine the dynamic changes of the Campylobacter population
in response to BCN treatment and to determine in vivo stability of BCN resistance in
Campylobacter. These studies are expected to provide important information that may
help avoid a rapid loss of efficiency of BCN and to design more sustainable and ‘smarter’
peptide antibiotics. In addition, examination of the molecular basis of BCN resistance in
Campylobacter may help us to develop more sustainable and effective BCN-based
intervention strategies against Campylobacter colonization in chickens. In this study, we
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revealed that active transport of multidrug efflux pump CmeABC confers resistance to
BCN in Campylobacter. Thus, inhibition of this pump by efflux pump inhibitors will
significantly increase susceptibility of Campylobacter to BCN. Previous studies (Lin et
al. 2006; Hannula et al. 2008) have shown that inhibition of efflux pump CmeABC in
Campylobacter spp resulted in increased susceptibility to various antimicrobials.
Notably, such an efflux pump inhibitor also could dramatically increase Campylobacter
susceptibility to intestinal bile salts by inhibiting CmeABC, leading to reduced
colonization of Campylobacter in chickens (Lin et al. 2006; Hannula et al. 2008).
Therefore, oral administration of the anti-Campylobacter BCNs together with such efflux
pump inhibitors using an appropriate delivery system (e.g., encapsulation) would enhance
the therapeutic effect of anti-Campylobacter BCNs. This speculation needs to be
determined in future studies.
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Table 8. Major bacterial strains and plasmids used in this study (Chapter III)
Strains or
plasmids
Strains
Campylobacter
JL106
JL20
JL349
JL241
JL28
JL199
JL341
JL4
JL360
JL199
JL424
JL416
JL372
JL3
JL219
JL377
JL358
K15A2
JL412
Plasmids
pGEM-T Easy
pCj1125c
pcmCj1125c
pCj1687
pcmCj1687
pRY111
pPerR
pCME
pRK2013
E.coli
DH5α
JL402
JL48

Description

C. coli strain isolated from human
C. coli strain isolated from pig
JL 20 derivative, BCNr mutant obtained from single step
selection in vitro
C. jejuni NCTC 11168 strain isolated from human
C.jejuni 81-176 isolated from human
NCTC 11168 derivative, cmeB::kan
NCTC11168 derivative, BCNr mutant generated by natural
transformation using genomic DNA of C. coli JL106
NCTC 11168 derivative, cmeR::cm
JL341derivative, cmeB::kan
NCTC 11168 cmeB::kan
JL360 containing shuttle vector pCME
JL341derivative, Cj1125c::cm
JL341derivative, Cj1687::cm
81-176 derivative, cmeB::kan
81-176 derivative, Cj0035c::cm
JL341derivative, Cj0035c::cm
81-176 derivative, BCNr mutant generated by natural
transformation using JL349 genomic DNA
JL358 perR::kan
K15A2/pPerR

Source or
reference
Human a
This study
This study
(Parkhill et al. 2000)
(Black et al. 1988)
(Lin et al. 2005)
This study

This study
(Lin et al. 2002)
This study
This study
This study
(Lin et al. 2002)
(Ge et al. 2005)
This study
This study
This study
This study

PCR cloning vector, Ampr
pGEM-T Easy containing 1.7 kb Cj1125c gene of JL241
pCj1125c with Cm resistance gene inserted in Cj1125c gene
pGEM-T Easy containing 2.0 kb Cj1687 gene of JL241
pCj1687 with Cm resistance gene inserted in Cj1687 gene
E.coli-C.jejuni shuttle vector, cmr
pRY111 derivative containing a 1.45-kb perR gene plus its
promoter region
pUOA18 shuttle vector derivative containing a wild-type
cmeABC operon
IncP Tra RK2+ repRK2 repE1+, Kanr

Promega
This study
This study
This study
This study
(Lin et al. 2002)
This study

F– 80lacZ M15 (lacZYA-argF)U169 recA1 endA1
hsdR17 (rk–, mk+) phoA supE44 thi-1 gyrA96 relA1 –
E.coli DH5α containing pPerR
Conjugation helper strain, DH5α containing plasmid RK2013

Invitrogen

a

(Lin et al. 2003)
(Ditta et al. 1980)

This study
(Akiba et al. 2006)

Isolated from human feces and kindly provided by Qijing Zhang (Iowa State
University).
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Table 9. Key oligonucleotide primers used in this study (Chapter III)
Primer
Cj1125cF
Cj1125cR
Cj1116cF
Cj1116cR
CmAfeI-F
CmAfeI-R
Cj1687F1
Cj1687R1
Cj0630cF
Cj0630cR
PerRF2
PerRR2
a

DNA Sequences (5’ - 3’) a
GCCCGCTAGAATGTCTTTGA
ATCTAACCCGGGACGATTTT
GGAACTCATTGATGAAATGCAA
CCCTACCATCTATAGGTGCAAAA
GCGAGCGCTTGCTCGGCGGTGTTCCTTT
GCGAGCGCTGCGCCCTTTAGTTCCTAAAG
TCTTTGGCATCTTTGGCTTT
TGCGATTTTGATGTTTCC
CAACGAAAAACAAAGCAA
TGTTTTTAAGTTCTTCGATTTTTGC
AAACAAGTAAGGTGGAA
AGTGCAATCAGATAGTAAA

Restriction sites are underlined in the primer sequences
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Product
size

Gene amplified

1733

Cj1125c

1982

Cj1116c

811

cmr cassette

2000

Cj1687

1350

Cj0630c

1662

Cj0032 (perR)

Table 10. Frequency of emergence of BCN resistant Campylobacter in vitro
BCN
conc.
(μg /mL)
4
8
16
a

Frequency of emergence of BCN resistance for each straina
C. jejuni
81-176
<9.2x10-9
<9.2x10-9
<9.2x10-9

C. coli

11168
S3B
-10
<2x10
<1.5x10-10
<2x10-10 <1.5x10-10
<2x10-10 <1.5x10-10

JL20
(3.5 ± 1.0)x10-7
(1.8 ± 1.6)x10-7
(1.5 ± 1.4)x10-8

JL25
(8.7 ± 5.6)x10-7
(1.1 ± 1.0)x10-7
(1.7 ± 1.4)x10-8

The values are means of two independent experiments with triplicate measurements.
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Table 11. Horizontal gene transfer of BCN resistance in Campylobacter spp

Donor strains
(C. coli)
C. coli JL106
(MIC = 64)
C. coli JL349
(MIC = 32)

Recipient
strains
C. jejuni
NCTC11168
C. jejuni 81-176
C. coli JL20
C. coli JL25

Transformation
frequencya
(transformants/μg DNA/
recipient CFU)
1.2 x10-8
1.0 x10-8
4 x10-7
4 x10-7

a

Highest MIC of
selected
transformants
(μg/ml)
8 (JL341)
16 (JL358)
16
16

The values are from a representative experiment with duplicate measurements within
each independent experiment.
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Table 12. Differentially expressed genes ( ≥ 2-fold change) in NCTC 11168 BCNr mutant
JL341 identified by microarray
Gene

Function description

Fold change
(microarray)

Up-regulated genes
Cj0366c
Inner membrane transporter of CmeABC efflux system
(cmeB)
Cj0365c
Outer membrane component of CmeABC efflux system
(cmeC)
Cj0630c
DNA polymerase III, delta subunit
Cj1726c
Putative homoserine O-succinyltransferase
Cj1116c
Putative membrane bound zinc metallopeptidase
Cj1125c
Putative galactosyltransferase (wlaG/pglA)
Cj0176c
Putative lipoprotein
Cj1687
Putative efflux transporter (MFS family)
Cj0035c
Putative efflux transporter (MFS family)
Down-regulated genes
Cj0508
Penicillin-binding protein
Cj0093
Putative periplasmic protein
Cj0628
Putative lipoprotein
Cj0045c
Putative iron-binding protein
Cj0091
Putative lipoprotein
Cj0629
Putative lipoprotein
Cj1423c
Putative sugar-phosphate nucleotidyltransferase
Cj1650
Hypothetical protein
Cj1714
Small hydrophobic protein
Cj1539c
Putative anion-uptake ABC-transport system protein
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P-value

4.9

5.93E-06

4.0

2.72E-05

13.5
2.0
4.8
12.8
2.0
2.0
3.4

4.63E-04
8.31E-04
4.00E-03
5.50E-03
7.05E-03
2.14E-02
2.19E-02

-4.5
-2.5
-2.9
-2.0
-2.5
-2.7
-2.7
-17.9
-2.4
-2.1

2.37E-05
1.49E-04
1.57E-04
6.60E-04
8.90E-04
1.16E-03
1.49E-03
1.80E-03
4.56E-03
9.39E-03

Table 13. CmeABC contributes to both intrinsic and acquired BCN resistance in C. jejuni
NCTC 11168
Strains

Description

JL241
JL199
JL4
JL341
JL360
JL424

Wild type NCTC 11168
NCTC 11168 derivative, cmeB::kan
NCTC 11168 derivative, cmeR::cm
NCTC 11168 derivative, BCNr mutant
JL341 derivative, cmeB::kan
JL360 containing pCME for complementation of cmeB
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MICs of OR-7
(µg/ml)
0.5
0.125
1
8.0
2
8

Table 14. Identification of transposon mutants with increased sensitivity to BCN
compared to MIC of 16 μg/ml for parent strain JL358
Strain

MICs of
BCN
(μg/ml)

Locus
designation

Tn location
(ORF size, bp)a

Function of inserted gene
product

K15A2

4

Cj0322 (perR)

54 (411)

Fur family regulator

K17E10

4

Cj0367c (cmeA)

557(1104)

Component of CmeABC pump

K16H6

4

Cj0366c (cmeB)

790(3123)

Component of CmeABC pump

K11A10

4

Cj0365c (cmeC)

107(1479)

Component of CmeABC pump

K1H1

4

Cj0366c (cmeB)

1679(3123)

Component of CmeABC pump

K15G10

4

Cj0365c (cmeC)

1213(1479

Component of CmeABC pump

a

The number indicates the nucleotide before which the transposon (Tn) is inserted.
ORF, open reading frame.
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Number of isolates

90
80
70
60
50
40
30
20
10
0

C.jejuni

0.25

0.5

1

2

C.coli

4

64

MIC of BCN
Figure 2. Prevalence of Campylobacter spp isolates resistance to bacteriocin. 137 C.
jejuni and 20 C. coli isolates were examined for the susceptibility to BCN OR-7 and E760 using MIC tests. Open bars represent C. jejuni isolates. Black bars represent C. coli
isolates.
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CHAPTER IV

DEVELOPMENT AND STABILITY OF BACTERIOCIN RESISTANCE IN
CAMPYLOBACTER
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ABSTRACT

Bacteriocins (BCNs) are antimicrobial peptides produced by bacteria with narrow
or broad ranges of antimicrobial activity. Recently, several unique anti-Campylobacter
BCNs have been identified in commensal bacteria isolated from chicken intestines. These
BCNs dramatically reduced C. jejuni colonization in poultry and are being directed
toward on-farm control of Campylobacter. Our previous study in Chapter III
demonstrated that Campylobacter could develop resistance to BCNs in vitro. However,
no information exists concerning in vivo development and stability of BCN resistance in
Campylobacter, an important issue needing to be addressed for practical application of
BCN-based intervention measures. In this study, development and stability of BCN
resistance were examined. For the in vivo development of BCN resistance, chickens that
have been colonized by C. jejuni NCTC 11168 were fed with BCN E-760 at dose of 5
mg/kg body weight for three consecutive days. For in vivo stability of BCN resistance,
groups of chickens were fed one of three BCNr Campylobacter strains obtained from
different sources. Total and BCNr C. jejuni populations in fecal samples from both
studies were determined by differential plating using selective plates with or without
BCN E-760. In addition, in vitro stability was tested by repeated subculturing of the
BCNr mutants in BCN E-760-free broth medium followed by differential plating. Our
results showed that C. jejuni could develop resistance to BCN in vivo. However, the
BCNr mutants only accounted for 0.0005% of the total C. jejuni population in the feces.
MIC tests indicated all mutants displayed low-levels of resistance to E-760 with MIC
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values ranging from 2 to 8 µg/ml. Inactivation of the CmeABC efflux pump of the BCNr
mutants led to increased susceptibility to E-760. The low-level of BCN resistance was not
stable in vivo, and BCNr mutants were not detected at day 42 after inoculation. BCN
resistance was also not stable after 10 passages in vitro; more than 95% of BCNr
Campylobacter spp were sensitive to the BCN after 35 passages. This study highlights
the significance of in vivo usage of BCN for Campylobacter control in poultry. BCN
selected only low-level BCNr C. jejuni mutants in vivo and the low-level BCN resistance
was not stable both in vivo and in vitro.
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INTRODUCTION
Campylobacter species, the epsilon class of proteobacteria, are the leading
bacterial causes of human gastroenteritis in developed countries (Allos 2001). In addition
to watery diarrhea and/or hemorrhagic colitis, infection with Campylobacter spp can
result in post-infectious manifestations such as Guillain-Barre’ syndrome, an acute
immune mediated disorder that may lead to respiratory muscle compromise and death
(Nachamkin et al. 1998). Campylobacter spp are considered to be commensal organisms
in the intestinal tract of wild and domestic animals including chicken and other avian
species (Diker et al. 2000). Epidemiological studies demostrated that consumption of
contaminated poultry meat is the major cause of human campylobacteriois (Stern et al.
2001; Cox et al. 2002; Stern et al. 2004). Thus, on-farm control of Campylobacter spp
could reduce risk of human Campylobacter infection. Of the several proposed strategies
to reduce this risk, anti-Campylobacter bacteriocins (BCNs) are considered a promising
strategy to protect food safety and public health (Lin, 2009).
BCNs are short cationic antimicrobial peptides naturally produced by diverse
microbes in different environments (Willey et al. 2007). Despite significant structural and
characteristic differences, BCNs display potent antimicrobial activities against a wide
range of viruses, bacteria, and fungi with diverse modes of action and have been
recognized as a novel class of antimicrobials to control foodborne pathogens (Hugas et al.
1998; Zasloff 2002; Galvez et al. 2007; Settanni et al. 2008). As a group of natural
antimicrobials, some BCNs, such as nisin, have long been applied for food preservation.
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More than 99 percent of bacteria including intestinal commensals can make at least one
bacteriocin (Klaenhammer 1988; Riley et al. 1992). Therefore, intestinal BCN-producing
bacteria may achieve a competitive advantage and function as an innate barrier against
pathogens in the hosts. The natural BCNs have been proposed as promising candidates
for novel antimicrobials (Joerger 2003; Asaduzzaman et al. 2009).
Several anti-Campylobacter BCNs were successfully isolated and characterized
from chicken commensal bacteria, which includes OR-7 from Lactobacillus salivarius
(Stern et al. 2006), E-760 and E50-52 from Enterococcus faecium (Line et al. 2008;
Svetoch et al. 2008), and SRCAM from Paenibacillus polymyxa (Stern et al. 2005).
Animal studies have demonstrated that these BCNs dramatically reduced C. jejuni
colonization in the intestine and these BCNs are being developed toward on-farm control
of Campylobacter to protect public health. Although the anti-Campylobacter BCNs are
very effective in reducing C. jejuni colonization in poultry, several important issues (e.g.
production, safety, and development and stability of resistance) need to be addressed for
future regulatory approval and public acceptability of this intervention measure. The
study in chapter III has demonstrated that Campylobacter could develop low-level BCN
resistance in vitro. However, no information exists concerning in vivo development and
stability of BCN resistance in Campylobacter. Using both in vitro and in vivo systems,
we showed the in vivo usage of BCN selected only low-level BCNr C. jejuni mutants and
the low-level BCN resistance was not stable under both in vitro and in vivo conditions.
This study provides helpful information for risk assessment of the future practical
application of the anti-Campylobacter BCNs in poultry.
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MATERIALS AND METHODS

Bacteriocin E-760, bacterial strains and growth conditions. Bacteriocin E-760
(Line et al. 2008) was kindly provided by Dr. Norman J. Stern (USDA/ARS). E-760 was
dissolved in distilled water and stored at -200C prior to use. The major bacterial strains
used in this study are listed in the Table 15. All strains were routinely grown in MH broth
or agar at 420C under microaerophilic conditions generated using a CampyGen Plus gas
pack (Oxiod, Lenxa, KS) in an enclosed jar. When needed, E-760 was added in MH agar
at desired concentrations.
in vivo development of BCN resistance in Campylobacter. The in vivo
development of BCN resistance in Campylobacter was examined using a chicken model
system. In this experiment, day-old broiler chicks (a kind gift from commercial company
Hubbard Hatchery, Pikeville, TN) were randomly assigned to either treatment (10 chicks)
or control groups (10 chicks). All birds were placed in sanitized wire cages with
unlimited access to feed and water. Nutritionally complete feed was prepared in the feed
mill at the Johnson Animal Research and Teaching Unit, the University of Tennessee.
Prior to inoculation with C. jejuni NCTC 11168, all birds were confirmed to be free of
Campylobacter by culture of cloacal swabs. At 2 days old, all birds in treatment and
control groups were inoculated with fresh C. jejuni NCTC 11168 cultures (107 CFU/bird)
via oral gavages. Three days after Campylobacter inoculation, all birds were examined to
ensure colonization by Campylobacter. For the treatment group, at 9 days of age, all birds
were treated with BCN E-760 at the dose of 5 mg/kg body weight/day via oral gavages
for three consecutive days. Birds in the control group were gavaged with water. Cloacal
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swabs were collected from all birds in both groups at day 1, 2, 3, 5, and 7 after the initial
BCN treatment. Samples from each bird were serially diluted and spread onto two
different plates: MH agar selective supplement (normal selective plates) to recover all
Campylobacter populations, and MH agar selective supplement plus E-760 with final
concentration of 16 µg/ml to recover BCN resistant populations. Campylobacter colonies
were counted following 48 hours of incubation at 420C under microaerophilic conditions.
Individual colonies from E-760 containing plates were randomly picked to identify level
of BCN resistance using MIC testing as described below. In addition, representative
colonies from BCN-free plates were also chosen for MIC test.
The detection limit of the plating method was approximately 100 CFU/g of feces.
The significant difference in Campylobacter colonization levels (log10 transformed
CFU/g of feces) at each sampling point between groups was calculated using Student’s t
test. A P-value of <0.05 was considered significant.
in vitro stability of BCN resistance. Three BCN resistant mutants were
examined for in vitro stability of acquired BCN resistance, which include a human
clinical isolate JL106 (E-760 MIC = 64 μg/ml), the in vitro-selected mutant JL341 (E-760
MIC = 8 μg/ml), and the in vivo-selected strain K58 (MIC = 8 μg/ml) (Table 15). Briefly,
the three strains were inoculated in E-760-free MH broth and grown under
microaerophilic conditions at 420C. The Campylobacter cultures were sub-cultured every
2 to 3 days in fresh MH broth (1:400 dilutions) for 70 days in the absence of any
antimicrobials. Following passages 10, 15, 20, 25, 30, and 35, the cultures were serially
diluted (10-fold dilutions) in MH broth and plated onto both MH agar plates and MH
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agar plates supplemented with E-760 at a concentration of 16 μg/ml. The plates were then
incubated in microaerophilic conditions at 420C for two days. Total numbers of colonies
on each type of plate were counted and compared for each time point. In addition,
following passage 35 differential plating, 20 colonies for each mutant were randomly
picked up from bacteriocin-free MH agar plates and were subjected to E-760 MIC test as
described below.
in vivo stability of BCN resistance using a chicken model system. The same
BCN resistant mutants were used for an in vivo stability test using a chicken model
system. Bird source and maintenance were the same as those used in the in vivo
development of BCN resistance experiment described above. Forty one-day old chickens
were randomly assigned into four groups (10 chickens each group). Prior (3 days) to
inoculation with Campylobacter, all birds were confirmed free of Campylobacter by
cultured cloacal swabs. Birds in each group received the corresponding Campylobacter
strain at a dose of 107 CFU/bird via oral gavage at 3 days old. Birds in the control group
were treated with wild-type, E-760 sensitive strain C. jejuni NCTC 11168. Birds in the
other three treatment groups were inoculated with JL106, JL341, and K58, respectively
(all strains displayed comparable growth level in vitro). Birds in all groups received
BCN-free feed and water throughout the trial. Cloacal swabs were collected from birds in
all groups at day 6, 22, and 42 after Campylobacter inoculation. Isolation of
Campylobacter spp and differential plating for enumerating the proportion of BCN
resistance mutants in the populations in each group were identified the same as the
chicken experiment described above. At each time point, representative colonies (40
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colonies) from chickens in each group were chosen for E-760 MIC test. Multiple isolates
with different E-760 MICs were analyzed by PCR to confirm their genetic identities. The
PCR was done using primers specific for the cmp gene encoding the major outer
membrane protein as described previously by Huang et al. (2005), which revealed no
difference between input strain and output isolates.
E-760 susceptibility test. The susceptibility of Campylobacter spp to E-760 was
determined by standard micro titer broth dilution method with an inoculum of 106
bacterial cells/ml that was described previously (Lin et al. 2002). Minimum inhibitory
concentration (MIC) was determined by the lowest E-760 concentration that completely
inhibited Campylobacter growth after 24 hours under microaerophilic condition at 420C.
Insertional mutagenesis of the cmeB gene in BCN resistant mutants. To
construct an isogenic cmeB mutant in Campylobacter in vivo-selected BCN resistant
mutants, genomic DNA of JL3 (Table 15), a cmeB mutant, was extracted and was used
for natural transformation by biphasic natural transformation as described previously
(Davis et al. 2008).

RESULTS

Effect of E-760 treatment on the emergence of BCN resistant Campylobacter
in chickens. In this experiment, all chickens in both groups were successfully colonized
by C. jejuni NCTC 11168 prior to E-760 treatment. The shedding levels of C. jejuni in
both groups were similar (approximately 5.5 log10 units). Throughout the trial C. jejuni
consistently colonized all chickens regardless of BCN treatment (Fig 3). E-760 resistant
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mutants were selected from one chicken in the BCN treated group one day after the first
treatment. Six days after the first treatment, 80% of chickens were found to shed E-760r
mutants (Fig 4). However, the E-760 resistant mutants only accounted for a small portion
of Campylobacter population in individual chicken (0.0005%). MIC test of 17 randomly
selected E-760 resistant Campylobacter isolates generated in vivo indicated that mutants
displayed low-level resistance to E-760 with MIC ranging from 2 µg/ml to 8 µg/ml
(Table 16). No chickens in the control group shed E-760 resistant mutants.
CmeABC

contributes

to

E-760

resistance

in

the

in

vivo-selected

Campylobacter isolates. Studies in chapter III have shown the multidrug efflux pump
CmeABC contributed to both intrinsic and acquired BCN resistance in Campylobacter.
However, it is unknown if CmeABC plays a role in E-760 resistance in the in vivoselected mutants obtained from this study. As shown in Table 16, regardless of resistance
level of a specific mutant, inactivation of cmeB significantly reduced E-760 MIC to 0.125
µg/ml, which is lower than the E-760 MIC for the wild-type strain NCTC 11168.
Bacteriocin E-760 resistance is not stable in vitro in the absence of BCN
selection pressure. As shown in Fig 5, less than 10% of JL341 populations could be
selected on MH agar plates containing 16 µg/ml of E-760 after 10 passages in the
absence of BCN selection pressure. Following 35 passages, only a very small population
of JL341 (0.0005%) were recovered on an E-760-containing plate. Although JL106 and
K58 showed higher stability than JL341 in vitro, less than 0.1% and 1% of JL106 and
K58, respectively, were selected on BCN-containing plates after 35 passages. The
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differential plating results were also confirmed by E-760 MIC tests of representative
colonies selected after 35 passages (data not shown).
in vivo instability of E-760 resistance in Campylobacter. All chickens were
successfully colonized by Campylobacter in both control (C. jejuni NCTC 11168) and
treatment groups inoculated with C. jejuni JL341, K58, or C. coli JL106 with shedding
levels of approximately 7 log10 units per gram feces at 6 days post inoculation (Fig 6A).
Unexpectedly, the percentage of chickens colonized with E-760 resistant strains
decreased after 22 days (JL106) and 42 days (JL341, K58, and JL106) of inoculation
(Table 17). The shedding levels of Campylobacter in colonized chickens were also
slightly reduced in both control and treatment groups at 22 and 42 days postinoculation
when compared to 6 days postinoculation (Fig 6A).
The in vivo stability of BCN resistance was monitored by differential plating as
well as E-760 MIC tests of randomly selected colonies (40 colonies per time point per
group). As showed in Fig 6B, percentage of E-760 resistant mutants decreased for all
three Campylobacter strains with time. By 42 days post inoculation, E-760 resistant
populations were less than 7% for all three resistant strains. The resistance levels were
also reduced to < 2 µg/ml for randomly selected resistant colonies (data not shown).

DISCUSSION
Several anti-Campylobacter BCNs have been successfully identified and
characterized from chicken commensal bacteria (Stern et al. 2005; Svetoch et al. 2005;
Stern et al. 2006; Line et al. 2008; Svetoch et al. 2008). Feeding these anti93

Campylobacter BCNs to poultry pre-slaughter eliminated Campylobacter colonization
(Stern et al. 2005; Svetoch et al. 2005; Stern et al. 2006; Line et al. 2008; Svetoch et al.
2008). Although these BCNs are very effective in reducing Campylobacter spp
colonization in poultry, the use of these anti-Campylobacter BCNs may lead to
emergence of BCN resistant isolates resulting in problems in the treatment of resistant
Campylobacter infection. Therefore, studying BCN resistance including development and
stability of resistance are crucially important for future regulatory approval and public
acceptability of this intervention measure. In our previous study discussed in Chapter III,
we demonstrated that Campylobacter spp could develop low levels of BCN resistance in
vitro. In this study, we examined the in vivo development BCN resistance in
Campylobacter using a chicken model system. Because BCNs have been proposed to be
fed to chickens for three consecutive days pre-slaughter to control Campylobacter (Cole
et al. 2006), a treatment regimen mimic clinical (3 consecutive days) with BCN was
applied in this study. Our data showed that in response to BCN treatment, BCN resistant
C. jejuni quickly emerged as early as one day after the first BCN treatment. However, the
BCN resistance in Campylobacter was low in terms of MIC (1 µg/ml to 8 µg/ml, even
after the third BCN treatment) and frequency (0.0005%) during the whole experiment.
This in vivo finding is consistent with the in vitro results described in Chapter III. In vivo
resistance development of Campylobacter to several antibiotics used as either therapeutic
or growth promotants has been well studied (Luo et al. 2003; Lin et al. 2007; Han et al.
2008; Lindow et al. 2010). A previous study (Lin, Yan et al. 2007) showed that
development of macrolide resistance in vivo was only observed after long-term exposure
to tylosin. Short-term treatment of Campylobacter-infected chickens with a high dose of
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macrolide also did not result in selection of Erythromycin resistance. However, long-term
treatment with a low dose of tylosin in feed resulted in the emergence of resistance
mutants with high levels of MIC (12 to 100% of tested isolates). The result in this study
revealed different patterns of resistance development for tylosin and BCN usage. The
BCN resistance appears to develop quickly but the MIC resistance levels of the mutants
are low in Campylobacter. However, the results should be interpreted cautiously because
the experiment was conducted in a laboratory environment using a small number of
chickens which does not represent the production conditions in most poultry farms. In
addition, a dose experiment should be performed to determine if greater selection
pressure would promote the development of mutants with high-level BCN resistance.
Finally, antibiotic resistance development on farms is very complex and influenced by
multiple factors such as animal species, production environment, genetic background of
bacterial species, and management practices.
In addition to demonstrating the development of BCN resistance, we also
observed dynamic changes in BCN resistance of individual chickens in this study. One
day after the first treatment, only 10% of the chickens in the treated group were positive
with BCN resistant Campyloabcter. Then, the number of chickens colonized by
resistance Campylobacter steadily increased during the course of treatment eventually
80% of chickens were found positive with BCN resistant Campylobacter two days after
the third treatment, and quickly dropped to 40% two days afterward (Fig 4). This finding
showed the 3-day BCN treatment exerted continuous selection pressure and resulted in an
increased number of chickens shedding BCN resistant mutants by 5 days after the first E-
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760 treatment. The resistance in Campylobacter is likely not stable due to fitness cost,
consequently resulting in clearance of BCN resistant Campylobacter after cessation of
BCN treatment. These speculations need to be further examined in future studies.
Multidrug resistance efflux pump CmeABC plays a prominent role in resistance
to various antimicrobials and chicken colonization (Lin et al. 2002; Lin et al. 2003). It
was shown in Chapter III that CmeABC contributed to both intrinsic and acquired
resistance to BCN for the mutants selected in vitro. This result suggests that CmeABC
plays a role in low level BCN resistance in Campylobacter in both in vivo and in vitro.
Thus, a combination of anti-Campylobacter BCN and CmeABC pump inhibitors could be
a feasible approach to eliminate Campylobacter colonization and reduce BCN resistance
in chickens.
Antibiotic resistance in bacteria is occurring as the result of either chromosomal
mutations or horizontal transfer of mobile genetic elements, such as plasmids, phages,
transposons, and integrons. These genetic changes may influence physiological processes
in microorganisms. Both chromosomal mutations and plasmid-mediated antibiotic
resistance, generally result in a fitness cost creating growth impairment and/or less
decreased competitiveness with antibiotic sensitive strains. The stability of antibiotic
resistance and fitness cost due to acquisition of antibiotic resistance are unique in
Campylobacter compared to other microorganisms. Our previous studies demonstrated
that low levels of macrolide resistance in Campylobacter associated with mutations in
ribosomal proteins L4 and L22 were unstable in vitro. In contrast, high levels of
macrolide resistance due to mutations at A2074G and A2075G in 23S rRNA were stable
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in vitro in the absence of macrolide selection pressure (Lin et al. 2007; Caldwell et al.
2008). Luo et al. (Luo et al. 2005) reported that fluoroquinolone (FQ) resistance in
Campylobacter associated with gyrA mutation is very stable in vivo and in vitro, and FQresistance strains did not show any fitness costs. FQ-resistance even enhances ecological
fitness and outcompetes FQ-sensitive strains when coinoculated in chickens. In our study,
both in vivo and in vitro experiments clearly showed that BCN resistance was not stable
regardless of Campylobacter species and resistance levels. This information is also
important for the risk assessment of using BCN in practical applications. For example, it
is likely that some BCN resistant Campylobacter mutants may be transmitted to a new
flock. However, based on the finding from this study, the BCN resistance trait will be lost
when these mutants colonize new a flock that receives BCN-free feed, consequently
having little effect on BCN treatment at pre-slaughter.
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Table 15. Major bacterial strains used in this study (Chapter IV)
Strains
JL3
JL106
NCTC 11168
JL341
K58

Description
NCTC 11168 derivative, cmeB::kan
E-760r C. coli; clinical strain isolated from
Human isolate, genome available
NCTC 11168 derivative, E-760r mutant
generated by transformation using genomic
NCTC 11168 derivative, E-760r mutant
selected from in vivo experiment
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Source and reference
(Lin et al. 2002)
This study
(Parkhill et al. 2000)
This study
This study

Table 16. E-760 MICs of the in vivo-selected E-760r C. jejuni isolates and their isogenic
cmeB mutants
Strain
C. jejuni NCTC 11168
E-760r mutants selected
in vivo

a

E-760 MIC (µg/ml)a
0.5
2 (3)

E-760 MIC of isogenic cmeB
mutant(µg/ml)
0.125
0.125

4 (4)

0.125

8 (10)

0.125

Numbers in parentheses indicate the total number of isolates corresponding to each
MIC.
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Table 17. Percentage of chickens colonized with Campylobacter spp
Strains
NCTC 11168
JL341
K58
JL106

Day 6 (%)
100
100
100
100

Day 22 (%)
100
100
100
30

101

Day 42 (%)
100
60
60
20

Treatment

8

Control

Log10 CFU/g feces

7
6
5
4
3
2
1
0
0

1

2

3

5

7

Days after the first BCN inoculation

Figure 3. Shedding levels of C. jejuni NCTC 11168 in chickens orally gavaged with
water (control) or BCN E-760 (treatment). In the treatment group, all birds were treated
with BCN E-760 at 5 mg/kg body weight/day via oral gavage for three consecutive days.
Each bar represents the mean log10 CFU/gram feces ± standard deviation in each chicken
group.
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% of chickens with
E-760r mutants

100
80
60
40
20
0
1

2

3

5

7

Days after the first BCN treatment

Figure 4. Percentage of chicken colonized with E-760 mutants following E-760
treatment. Each bar represents the percentage of chickens that shed E-760 resistant
mutants at each sampling point (n = 10).
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Percent of E-760r mutants

100
10
1
0.1
0.01
JL341

0.001

JL106

K58

0.0001
1

10

15

20

25

30

35

Numbers of passage
Figure 5. Stability of E-760 resistance in vitro. Three strains were passed in MH broth
without E-760 selection pressure as described in Materials and Methods. The percentage
of BCNr population was calculated based on differential plating using plates with or
without 16 μg/ml of E-760.
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A
Log10 (CFU/gram feces

NCTC 11168

JL341

K58

JL106

9
8
7
6
5
4
3
2
1
0
6

22

42

Days post inoculation

B

JL341

Percentage of E-760r
population

100

K58

JL106

50

0
0

6

22

42

Days post inoculation
Figure 6. Stability of BCN resistance in vivo. (A) Shedding levels of BCN resistant
Campylobacter strains in chickens colonized with Campylobacter. Chickens in each
group (10 birds/group) were inoculated with BCN sensitive strain NCTC 11168, or one
of E-760 resistant mutants (JL341, K58, or JL106). All chickens received nonmedicated
feed throughout the study. Each bar represents the mean of log10 CFU/gram feces ±
standard deviation of Campylobacter colonized chickens in each group; (B) The E-760
resistance was not stable in vivo. The percentage of BCNr population was calculated
based on differential plating using plates with or without 16 μg/ml of E-760.
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CHAPTER V

IDENTIFICATION AND CHARACTERIZATION OF GENES REQUIRED FOR
CAMPYLOBACTER RESISTANCE TO FOWLICIDIN-1, A CHICKEN HOST
DEFENSE PEPTIDE
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ABSTRACT
Antimicrobial peptides (AMPs) are critical components of host defense limiting
bacterial infections at the gastrointestinal mucosal surface. Bacterial pathogens have coevolved with host innate immunity and developed means to counteract the effect of
endogenous AMPs. However, AMP resistance mechanisms are still unknown in C. jejuni,
an important human foodborne pathogen with poultry as a major reservoir. In this study,
random transposon mutagenesis and targeted site-directed mutagenesis approaches were
used to identify genes contributing Campylobacter resistance to fowlicidin-1, a
representative AMP in chickens. In addition, a chicken experiment was performed to
determine the role of candidate genes in Campylobacter colonization in the intestine. An
efficient transposon mutagenesis approach (EZ::TNTM <KAN-2> Transposome) in
conjunction with microtiter plate screening identified three mutants whose susceptibilities
to fowlicidin-1 were significantly increased. Backcrossing of the transposon mutations
into parent strain confirmed that the AMP-sensitive phenotype in each mutant was
associated with the specific transposon insertion. Direct sequencing showed that these
mutants have a transposon inserted in the genes encoding the two-component regulator
CbrR, transporter CjaB, and a putative trigger factor (Tig). Based on the analysis of 12
Campylobacter genomes, a conserved gene cj1583c displayed high homology (up to 46%
similarity at the amino acid level) to sap, an AMP resistance gene identified in other
pathogens. Insertional inactivation of Cj1583c also significantly increased susceptibility
of Campylobacter to fowlicidin-1 in diverse strain backgrounds. In vivo administration
of CbrR, Tig, and SapB mutants showed a reduction in in vivo colonization. Together,
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these results have defined four C. jejuni genetic loci that will be useful for characterizing
the molecular basis of Campylobacter resistance to AMPs, a significant knowledge gap
in Campylobacter pathogenesis.

INTRODUCTION

Campylobacter is a major causative agent of human bacterial gastrointestinal
diseases worldwide (Allos 2001). Campylobacter is commonly found as a commensal
organism in the digestive tracts of a variety of wild and domestic animals. Commercial
poultry are considered the major reservoir for human campylobacteriosis (Moran et al.
2009). Most

Campylobacter infections are epidemiologically associated with

consumption of undercooked poultry meats; the remaining cases are due to other risk
factors including contaminated milk, water, and direct contact with infected pets (Lin
2009). To successfully colonize and persist in intestinal tracts of many animals and
humans, Campylobacter must have evolved a variety of mechanisms to counteract and
adapt to harsh conditions. Examination of how this important human pathogen adapts to
and evades host innate immunity may reveal targets for developing novel vaccine and
therapeutics to prevent and control Campylobacter infections in humans and animal
reservoirs.
Endogenous antimicrobial peptides (AMPs) belong to the most ancient and
efficient components of host defense. Defensins and cathelicidins are two major groups
of host AMPs that limit bacterial infections at the gastrointestinal mucosal surface (Bulet
et al. 2004; Wehkamp et al. 2007). Epithelial AMPs, such as β-defensins, have been
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observed to be induced in human intestinal epithelia upon infection by C. jejuni (Zilbauer
et al. 2005; Wehkamp et al. 2007). In addition to their significant role in host innate
defense, AMPs including chicken cathelicidin fowlicidin-1 (F-1) have been increasingly
recognized as a novel class of antibiotics (peptide antibiotics) to control pathogens (Xiao
et al. 2006; Bommineni et al. 2007). It is not surprising that many bacterial pathogens
have co-evolved with the host and developed means to counteract the effect of AMPs
(Yeaman et al. 2003; Peschel et al. 2006). Given the wide prevalence and successful
colonization of C. jejuni in intestinal tracts, C. jejuni should have acquired mechanisms to
resist AMPs widely present in the host. However, as an important strategy to evade
killing by innate immunity and by potential peptide antibiotics, AMP resistance
mechanisms are still largely unknown in C. jejuni. Availability of this information will
not only help us to develop more sustainable peptide antibiotics but also provide insights
into the delicate host-pathogen interactions and reveal novel intervention targets to
control Campylobacter infections in humans and animal reservoirs.
In this study, using chicken host defense peptide F-1 as a model peptide in
conjunction with random transposon mutagenesis as well as targeted mutagenesis, we
identified four genetic loci required for F-1 resistance in Campylobacter, which include a
two-component regulator CbrR, transporter CjaB, a putative trigger factor Tig, and Sap
that is homologous to the previously described transporter conferring resistance to AMPs
in other Gram-negative bacteria. Administration in vivo also demonstrated that these
genes play an important role in the colonization of Campylobacter in the intestine.
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MATERIALS AND METHODS

Bacterial strains, plasmids and growth conditions. The major bacterial strains
and plasmids used in this study are listed in Table 18. Among 174 Campylobacter
isolates used for testing susceptibility to chicken AMP F-1, 154 isolates were C. jejuni
and 20 isolates were C. coli. These Campylobacter strains were isolated from different
hosts and geographically diverse locations. Campylobacter strains were routinely grown
in MH broth (Difco) or MH agar at 420C under microaerophilic conditions generated by
using a CampyGen Plus gas pack in an enclosed jar or by using a tri-gas incubator. E.
coli strains were grown in Luria-Bertani (LB) broth with shaking (250 rpm) or on agar at
37ºC overnight. Antibiotics Kanamycin (Kan) or Chloramphenicol (Cm) was added in
medium at a desired concentration when needed.

AMP susceptibility testing. The susceptibilities of C. jejuni and C. coli isolates
to the chicken cathelicidin F-1 were determined by a standard microtiter broth dilution
method with an inocula of 106 bacterial cells/ml as described previously (Lin et al. 2002).
Minimum inhibitory concentrations (MICs) were determined by the lowest concentration
of specific antimicrobial showing complete inhibition of bacterial growth after two days
of incubation at 420C. Chicken cathelicidin F-1A (F-1) (22 amino acids in length with >
95% purity) was synthesized by Bio-Synthesis (Lewisville, TX).
in vitro selection of F-1 resistant C. jejuni. F-1 was used as the selective agent to
obtain spontaneous F-1 resistant mutants in vitro. Briefly, 0.1 ml of Campylobacter cells
(OD ~1.2) harvested from MH agar plates incubated overnight were spread on MH agar
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plates supplemented with different concentrations of F-1 (32 and 64 μg/ml). To increase
the chance to get F-1 resistant mutants, the C. jejuni cells were also grown and passed
five times (2-days for one passage) in MH broth containing sub-lethal concentration of F1 (4 μg/ml). After five passages, the bacterial cells then were spread on MH plates
containing a higher concentration of F-1 (64 μg/ml). F-1 resistant mutants were selected
from the plates after 4 days of incubation at 420C under microaerophilic conditions. All
these selected mutants were grown in MH broth and subjected to MIC test together with
the parent strain C. jejuni 81-176.
Random transposon mutagenesis. C. jejuni 81-176 (JL28 in Table 18) was
subjected to in vivo transposon mutagenesis using EZ::Tn5™<KAN-2> Transposome
(Epicentre) as detailed in our previous publication (Lin et al. 2009). Briefly, one
microliter EZ-Tn5 <KAN-2> TnP transposome complex containing 25 ng transposon
was used to electroporate C. jejuni JL28 competent cells. The Kanr transformants were
individually picked and inoculated in 96-well microplates. Following 2 days of
incubation, cultures of mutants were replicated into microtiter plates containing 4 μg/ml
of F-1 (2-fold reduction of MIC of the parent strain). Those mutants that could not grow
in F-1-containing media were selected from the initial plates and subjected to a second
screening to confirm increased sensitivities of the mutants to F-1. To confirm specific
genetic linkage between the transposon insertion and increased BCN susceptibility of
each mutant, backcrossing of the transposon mutations into the parent strain was
performed using natural transformation (Wang et al. 1990). The MICs of F-1 for the
backcrossed mutants were determined together with parent strain C. jejuni JL28. The
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specific transposon insertion site of each mutant was determined by directly sequencing
the genomic DNA (Lin et al. 2009). Sequence analysis was performed using DNAStar
software package.
Targeted mutagenesis of C. jejuni and complementation in trans. An isogenic
Cj1583c (designated as sapB) mutant of C. jejuni NCTC 11168 was constructed by
insertional mutagenesis according to our previous publication (Lin et al. 2005). Briefly,
approximately 2-kb of the complete Cj1583c was PCR amplified from C. jejuni JL241
genomic DNA using primer pairs of Cj1583c-R and Cj1583c-F (Table 19) and Taq DNA
polymerase (Promega). The PCR product was cloned into a pGEM-T Easy vector
(Promega) to generate pSapB. The chloramphenicol resistance gene cassette (cm) was
PCR amplified from plasmid pUOA18 (Wang et al. 1990) using PfuUltra® High-Fidelity
DNA polymerase (Stratagene) and primers of CmF and CmR (Table 19). The resulting
blunt-ended PCR product was purified and ligated into pSapB vector, which was digested
with Hind III prior to ligation, to generate the mutant construct pcmSapB (Table 18). The
construct pcmSapB, which serves as suicide vector, was then introduced into C. jejuni
JL241 and JL242 by biphasic natural transformation or electroporation (Wang et al.
1990; Lin et al. 2009). The putative sapB isogenic mutants of corresponding strains were
selected on MH agar containing 5 μg/ml of Cm. The inactivation of putative sapB
(Cj1583c) in mutant JL697 was confirmed by PCR (data not shown).
To complement cjaB mutation in JL657, a 2.7-kb fragment including 174 bp
upstream of cjaA covering promoter region to 193 bp downstream of cjaB stop codon
was PCR amplified from NCTC11168 using primer pairs of CjaAB-F and CjaAB-R
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(Table 19). The PCR was performed using pfu DNA polymerase (Stratagene) and the
blunt-ended PCR product was purified and ligated to shuttle vector pRY111 (Yao et al.
1993), which was digested with SmaI prior to ligation. The ligation mix was introduced
into DH5α by transformation. One transformant (JL690) with a plasmid bearing an intact
cjaAB operon was created. The pCjaAB from JL690 was then transferred to JL657, a
cjaB isogenic mutant, by tri-parental conjugation using DH5α/pRK2013 as a helper strain
(Lin et al. 2005). A similar approach was used to complement tig and cbrR mutations
using primer pairs of Td-F/Td-R and Cj0643-F/Cj0643-R (Table 19), respectively. The
insertion of cjaAB, tig, or cbrR sequence in shuttle vector pRY111 was confirmed by
sequencing using specific primers.
Prevalence of sap genes among Campylobacter species. To examine the
prevalence of sapA and sapB in C. jejuni and C. coli, sapA and sapB sequences of 12
Campylobacter

strains

in

Campylobacter

a

data

bank

(CampyDB,

http://xbase.bham.ac.uk/campydb) were obtained and aligned using the Clustalw
program. The conserved domains of sapA and sapB were used to design specific primers
for PCR amplification of sapA and sapB, respectively (Table 19). The primers were used
to examine the prevalence of sapA and sapB in nineteen Campylobacter strains including
fifteen C. jejuni strains and four C. coli strains.
F-1 killing assay. The F-1 killing assay was performed in a 96-well plate as
described previously (Mount et al. 2010) with minor modifications. Briefly,
Campylobacter strains were grown in MH broth to mid-log phase, and the cells were
washed with MH broth and diluted to approximately 106 CFU/ml in MH broth. A volume
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of 180 μl of the diluted cells was mixed with 20 μl MH broth (control) or F-1 stock (80
μg/ml) (treatment). The plates were incubated under microaerophilic conditions at 420C
for 2 hours. After 2-hour incubation, 20 µl of bacterial culture were taken and serially
diluted in MH broth and plated onto MH agar plates. The number of CFU was
enumerated after 2 days of incubation under microaerophilic conditions at 420C.
Percentage survival was calculated by dividing the CFU of bacteria incubated with F-1
relative to those incubated in the presence of MH broth and then multiplied by 100. All
assays were done in triplicate and two independent experiments were performed. The
significance of differences in susceptibility was determined using the Student’s t-test.
Chicken colonization experiment. One-day-old broiler chickens were obtained
from a commercial hatchery (Hubbard Hatchery, Pikesville, TN). The chickens were
negative for Campylobacter as determined by culturing cloacal swabs prior to use in this
study. These chickens were randomly assigned into three treatment groups (10 or 11
chicks/group). At 4 days of age, each chicken was orally inoculated with a 1:1 mixture of
wild type 81-176 (JL242) and its isogenic cjaB mutant (group I), tig mutant (group II), or
sapB mutant (group III), with a dose of approximately 107CFU of bacteria per chick. For
each group, five birds were euthanized and cecal content were collected at 3 and 10 days
postinoculation (DPI). The cecal content from each bird were weighed and diluted in MH
broth. The cecal suspensions were duplicate plated onto MH agar plates with
Campylobacter-specific selective supplements (Oxoid, United Kingdom) for total
Campylobacter enumeration and onto selective plates supplemented with appropriate
antibiotics (30 µg/ml of Kan or 6 µg/ml of Cm) for the specific mutant numbers in each
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sample. The plating media were tested prior to use to ensure that they supported the
growth of the mutant strains. Notably, before inoculation, the motility of the wild-type
and its isogenic mutants were confirmed to be at a comparable level. The number of CFU
per gram of cecal contents was calculated for each chicken and was used as an indicator
of the colonization level. The detection limit of the plating methods was 100 CFU/g of
cecal contents. The bird from which no Campylobacter colonies were detected was
assigned a conservative value of 99 CFU/g of cecal content for the purpose of calculating
means and for statistical analysis. The significant difference in Campylobacter
colonization levels (log10 transformed CFU) at each sampling point within group was
calculated using Student’s t test. A P-value of < 0.01 was considered significant.

RESULTS

Susceptibilities of Campylobacter to chicken cathelicidin F-1. As shown in
Table 20, the majority of C. jejuni and C. coli isolates exhibited susceptibility to chicken
cathelicidin F-1 with MICs ranging from 4 μg/ml to 8 μg/ml. Only one C. jejuni strain
showed a slightly higher MIC of 16 μg/ml.
in vitro selection of F-1 resistant mutants. Different in vitro selection methods
led to the emergence of F-1 resistant mutants on the selective plates. A total of 8 mutants
were selected for MIC testing together with the parent strain 81-176. However, after
being cultured in F-1 free MH broth, none of these mutants displayed a higher MIC than
81-176 for F-1, indicating all these mutants were false-positive. Despite extensive efforts,
no F-1 resistant mutants were selected in vitro.
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Identification of genetic loci contributing to F-1 resistance by random
transposon mutagenesis. A library containing 4,800 Kanr mutants were generated to
screen for increased susceptibility to F-1. Three mutants displaying increased sensitivity
to chicken cathelicidin F-1 compared to the parent strain JL28 were identified (Table 21).
Backcrossing of the transposon mutations into the parent strain by natural transformation
further confirmed that the F-1-sensitive phenotype in each mutant was linked to the gene
with a specific transposon insertion. Direct sequencing of the mutant genomic DNA
using transposon-specific primers revealed a specific transposon insertion site in each
mutant (Table 21). All the transposon insertions occurred in the coding regions of
corresponding genes. The orientation of Kanr cassette within the transposon of each
mutant was the same as the corresponding disrupted gene.
F-1 killing assays were further performed to confirm if these three transposon
mutants displayed higher susceptibility to F-1 than 81-176. As shown in Fig 8A,
inactivation of CbrR, CjaB, or Tig led to increased susceptibility (5 to 12-fold) to F-1
compared with their parent strain 81-176. However, only complementation of CjaB
mutant with wild-type CjaB restored F-1 resistance back to the level of parent strain;
complementation of CbrR and Tig did not affect F-1 sensitivity of the mutants. In
addition, inactivation of CbrR, Tig, or CjaB alone in other strain background (NCTC
11168 and S3B) also led to increased susceptibilities of the mutants to F-1 (Fig 8B).
SapB is required for F-1 resistance in C. jejuni. The sap genes in Haemophilus
influenza confer AMP resistance in this bacterium (Mason et al. 2005). A BLAST search
of this study identified genes homologous to the sap genes identified in H. influenza 86116

028NP (Mason et al. 2005), which include periplasmic solute peptide binding protein
Cj1584c (25% aa identity to SapA), membrane permease proteins Cj1583c (20% aa
identity to SapB), Cj1582c (21% identity to SapC). Cj1581c (25% aa identity to SapD),
and Cj1580c (26% aa identity to SapF). However, the sapZ identified in H. influenza is
not located on the sap opreron in Campylobacter; the SapZ homolog Cj0999c (32% aa
identity) was identified in a separate region in C. jejuni NCTC 11168 genome. Isogenic
SapB mutants were created in C. jejuni 81-176 and NCTC 11168. As shown in Fig 8C,
inactivation of SapB resulted in increased sensitivity to F-1 (~4-fold) compared with their
parent strains.
Two pairs of primers (Sap4-F, Sap4-R) and (Sap5-F, Sap5-F) (Table 19) were
used to amplify a conserved fragment of sapB and sapA, respectively, in 19
Campylobacter strains. The PCR survey showed that majority of strains contains sapB
(17 out of 19) and sapA (15 out of 19) genes.
Genomic organization of the genes involved in F-1 resistance. As shown in Fig
7A, cjaB operon consists of two genes cjaA and downstream cjaB (Wyszynska et al.
2006). The tig operon contains two genes encoding trigger factor (Tig) which may
function as a chaperon facilitating folding of nascent peptides (Martinez-Hackert et al.
2009) and an ATP-dependent Clp protease, proteolytic subunit ClpP which was
demonstrated to be involved in stress tolerance and virulence in Campylobacter and other
bacteria (Cohn et al. 2007; Frees et al. 2007; Ingmer et al. 2009) (Fig 7B). Sequence
analysis showed that both trigger factor and ClpP are highly conserved in Campylobacter
spp (data not shown). The clpP is separated from its downstream gene def by a 28-bp
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intergenic

region

which

is

predicted

to

contain

a

promoter

sequence

(http://www.fruitfly.org/seq_tools/promoter.html). Thus, tig operon probably contains
two genes, trigger factor and clpP. Similarly, genetic organization of the cbrR operon was
analyzed and presented in Fig 7C. The cbrR operon contains ten genes and the functions
of the majority of these genes are not understood. The gene cbrR encoding a response
regulator was demonstrated to be involved in bile salt resistance and in vivo colonization
in Campylobacter (Raphael et al. 2005). Finally, in Fig 7D, putative sap operon contains
five genes cj1584c (sapA), cj1583c (sapB), cj1582c (sapC), cj1581c (sapD), and cj1580c
(sapF).

Tig, CjaB, and SapB are required for Campylobacter optimal colonization in
chickens. Since the identified genes confer resistance to F-1 in vitro, it is likely that these
genes also contribute to colonization of Campylobacter in chicken by mediating
resistance to F-1. It has been demonstrated that cbrR is required for optimal colonization
of Campylobacter in chickens (Raphael et al. 2005). Here we examined the role of cjaB,
tig and sapB in colonization of Campylobacter in chickens. As shown in Fig 9A, B, and
C, inactivation of cjaB, tig, or sapB greatly impaired the colonization ability of C. jejuni
81-176 in chickens. Specifically, when the wild-type and its specific isogenic mutant
were coinoculated into a group of chickens, the colonization level of the specific mutant
was significantly (P < 0.01) lower than that of the corresponding wild-type strain at 10
days post-inoculation (DPI). In particular, by 10 DPI, the specific mutant of C. jejuni 81176 (tig-, cjaB-, or sapB- mutant) was no longer detected in any of the cecal samples
collected from the chickens inoculated with a mixture of JL242 and its isogenic mutant.
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Notably, both the wild-type and its isogenic mutants showed comparable growth patterns
in MH broth (data not shown).

DISCUSSION

Our comprehensive survey using Campylobacter strains demonstrates the potent
killing activity of F-1 against Campylobacter from various origins and geographically
diverse regions. The unsuccessful generation of F-1 resistant Campylobacter mutants,
using cells grown in MH broth that was free of F-1 or containing sublethal concentrations
of F-1 strongly suggest that it is difficult for Campylobacter to develop acquired
resistance to chicken host defense peptide F-1. Recently, it has been proposed that AMPs
exert killing activity via interaction with multiple low-affinity targets. Therefore,
conceptually it is very difficult for bacteria to develop resistance to AMPs while highlevel resistance to most clinical antibiotics (e.g. fluroquinolone) would be developed
quickly due to their specific and high affinity target (Peschel et al. 2006). The findings
from this chapter and the BCN studies in chapter III and IV strongly support this theory
that bacteria have not developed highly effective mechanisms to resist various AMPs
during evolution (Peschel et al. 2006). Consequently, either BCNs or endogenous AMPs
are promising antibiotic alternatives (peptide antibiotics) to control bacterial pathogens.
Mechanisms of Campylobacter resistance to endogenous defense AMPs are
largely unknown. Alteration of LOS in the Campylobacter outer membrane led to altered
susceptibility to the host antimicrobial peptide cathelicidin (Naito et al. 2010; van Mourik
et al. 2010). In Campylobacter LOS synthesis, two genes gnnA and gnnB facilitate the
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formation of a 2, 3-diamino-2,3-dideoxy-D-glucose (GlcN3N) disaccharide lipid A
backbone when compared with the -1-6-linked D-glucosamine (GlcN) disaccharide
observed in E. coli lipid A. van Mourik et al 2010 demonstrated that inactivation of gnnA
and gnnB resulted in lipid A alternation and consequently increased sensitivity of the
mutants to chicken cathelicidin F-1 (van Mourik et al. 2010). Truncation of LOS core in
different locations resulted in altered sensitivity to human cathelicidin LL-37 (Naito et al.
2010).
In this study, inactivation of Campylobacter bile salt resistance regulator (CbrR)
resulted in increased sensitivity to F-1 and reduced colonization ability in chickens
(Raphael et al. 2005). However, the CbrR complemented strain did not restore resistance
back to wild type. Transposon insertion in cbrR may yield polar effects on downstream
genes. Notably, the gene Cj0649 encodes a beta-barrel OstA protein, known as LptD
which functions in the assembly of LPS in the outer leaflet of the outer membrane in
Gram-negative bacteria (Srinivas et al. 2010) and LOS modification in Campylobacter
altered host cathelicidin susceptibility (Naito et al. 2010; van Mourik et al. 2010). Thus, it
is likely that LOS synthesis defect may result in increased susceptibility to F-1.
The gene encoding efflux pump CjaB is widely distributed in Campylobacter
species and is located downstream of cjaA, and likely these two genes are organized in
the same operon (Wyszynska et al. 2006). Classification of transporter CjaAB is
intriguing at this stage (Wyszynska et al. 2006). In this study, we identified
Campylobacter transporter CjaB that contributes to F-1 resistance in vitro and
colonization of Campylobacter in chickens. In the chicken digestive tracts,
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Campylobacter has to interact with multiple antimicrobials and toxic substances
including chicken antimicrobial peptides (cathelicidin known as fowlicidin, and
defensins). Using efflux pumps (Lin et al. 2002; Akiba et al. 2006; Lin et al. 2006) to
extrude toxic compounds is critical for Campylobacter persistence and colonization in
chickens. At this point, the fowlicidin concentration in chicken intestine and
comprehensive in vivo information on substrates for the CjaAB efflux transporter are still
unknown. Thus, a defect in the colonization ability of the Campylobacter CjaB mutant is
likely the result of multiple actions of other unknown toxic compounds in the digestive
tract. This speculation needs more studies to identify and characterize the transporter
CjaAB and its cognate substrates.
Trigger factor (Tig) was found highly conserved in eubacteria, functioning as a
chaperon to interact with newly synthesized polypeptides and assist their folding as they
emerge from the ribosome (Rassow et al. 1996). In Campylobacter, the gene encoding
trigger factor (Tig) is located upstream of clpP which has proteolytic activity to degrade
misfolded proteins and plays a critical role in protein quality control in bacteria (Frees et
al. 2007). Inactivation of Tig by transoposon resulted in increased sensitivity to F-1 in
Campylobacter. However, complementation of Tig did not restore F-1 resistance back to
wild type strain, suggesting the tig downstream gene clpP may be indeed responsible for
F-1 resistance. ClpP mutant resulted in increased sensitivity of Campylobacter to stress
conditions such as heat and reduced virulence (Cohn et al. 2007). Shauna M. Mc
Gillivray (ASM 2010 meeting) demonstrated that a ClpP mutant resulted in increased
sensitivity of Bacillus anthracis to antimicrobialsl, including human cathelicidin LL-37
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(ASM 2010 meeting). This information strongly suggests the importance of the tig
operon in F-1 resistance and in vivo colonization of Campylobacter in chickens. It is
noteworthy that defective colonization of Campylobacter Tig mutant in chickens might
not be solely the result of increased susceptibility to F-1, but as a consequence of
increased susceptibility to overall stress conditions in the chicken intestine such as
temperature, bile salts, and other toxic compounds.
Our random transposon mutagenesis library (4,800 mutants) was not large enough
to identify all gene candidates, and thus failed to identify previously known genes
contributing to fowlicidin resistance such as relevant LOS genes (Naito et al. 2010; van
Mourik et al. 2010). Bacteria have co-evolved resistance to host AMP and resistance to
AMP as a combination of multiple components (Peschel et al. 2006). Thus, technical
limitation of random transposon mutagenesis capable of selecting the mutants with at
least two fold increased sensitivity could not identify all mutants with mildly increased
susceptibility (less than two-fold reduction in MIC) to F-1.
Sap transporters that belong to the ABC-type influx transporter have been
demonstrated to be required for AMP resistance in various Gram-negative bacteria
including Salmonella enterica serovar Typhimurium, Proteus mirabilis, Erwinia
chrysanthemi, and Haemophilus ducreyi (Parra-Lopez et al. 1993; Lopez-Solanilla et al.
1998; McCoy et al. 2001; Mason et al. 2005; Mount et al. 2010). Inactivation of the Sap
transporter resulted in defects in colonization in animal models (Lupp et al. 2002; Mason
et al. 2005; Mason et al. 2006; Mount et al. 2010). However, the Sap transporter does not
always confer AMP resistance in all bacteria expressing sap genes (Lupp et al. 2002).
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Thus, Sap transporters may display distinct functionality within bacterial species to
comply with the demands of that particular pathogen. In our study, a homolog to
SapABCDFZ of non-typeable Haemophilus influenza 86-028NP was identified among
Campylobacter species. Inactivation of SapB resulted in increased susceptibility to F-1
(but not to other AMPs such as bacteriocins OR-7, E-760, magainin and cecropin A,
using MIC tests, data not shown) and caused colonization defects in a chicken model
system. The gene sapB and sapA were amplified from a majority of Campylobacter
species including C. jejuni and C. coli. These results suggest the specific functionality of
Sap transporter in resistance to F-1A and in vivo colonization. The mechanisms of how
Sap transporters protect the cells from AMP attack are still unknown. It is generally
believed that AMPs exert bacterial killing activities by inserting cationic peptides into the
cytoplasmic membrane and form channels that result in leakage of cytoplasmic contents
(Hancock et al. 2006; Peschel et al. 2006). Because Sap transporters function as influx
pump, it is likely that Sap transporters reduce AMP localization in the periplasmic space
by pumping these AMPs into bacterial cytosol and consequently subjecting them to
enzymatic degradation. More studies to compare the fate of AMP in wild type and
different sap isogenic mutants could shed light on mechanisms of Sap-mediated
resistance to different AMPs in Campylobacter. We are currently examining functions of
each individual sap gene.
In this study, using F-1 as a model peptide to study chicken AMP resistance in
Campylobacter, four genes were identified contributing to F-1 resistance. However, at
this time, there are at least eighteen chicken AMPs (fourteen defensins and four
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cathelicidins) that have been identified and characterized (Xiao et al. 2006; Lynn et al.
2007). Thus, more studies are needed to test if these identified genes are also required for
resistance to other chicken AMPs such as defensins. Taken together, our study provided
comprehensive information on mechanisms of F-1 resistance in Campylobacter.
Campylobacter has utilized various strategies in conferring resistance to chicken host
antimicrobial peptide F-1 to persist and colonize in chickens. Although our results did not
pinpoint the exact mechanisms which Campylobacter utilizes to resist killing by F-1, the
information in this study provides a solid foundation to further characterize the
mechanisms of F-1 resistance in Campylobacter that will help us better understand
Campylobacter-chicken host interaction and facilitate development of effective measures
to reduce Campylobacter loads in chickens.
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Table 18. Major bacterial strains and plasmids used in this study (Chapter V)
Strains or
Description
Source and reference
plasmids
C. jejuni
JL241
JL28
JL242
JL599
JL628
JL623
JL656
JL601
JL665
JL657
JL602
JL629
JL658
JL668
JL694
JL695
JL624
JL631
JL697
JL706
Plasmids
pRY111
pCbrR
pTig
pCjaAB
pGEM-T Easy
pSapB
pcmSapB

NCTC 11168, human isolate
81-176, human isolate, unable to colonize in
chicken
81-176, human isolate, can colonize in chickens
JL28 derivative, cbrR::kan
JL599/pCbrR
JL241 derivative, cbrR::kan
JL242 derivative, cbrR::kan
JL28 derivative, cjaB::kan
JL241derivative, cjaB::kan
JL242 derivative, cjaB::kan
JL28 derivative, tig::kan
JL241derivative, tig::kan
JL242 derivative, tig::kan
JL656/pCbrR
JL657/pCjaAB
JL658/pTig
C. jejuni S3B derivative, cbrR::kan
C. jejuni S3B derivative, tig::kan
JL242 derivative, cj1583c::cm
JL241 derivative, cj1583c::cm

(Parkhill et al. 2000)
(Black et al. 1988)
(Black et al. 1988)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

E.coli-C.jejuni shuttle vector, Cmr
pRY111 containing cbrR
pRY111 containing tig
pRY111 containing cjaAB
Cloning vector, Ampr
pGEM-T Easy containing sapB, Ampr
pSapB with cm inserted sapB

(Yao et al. 1993)
This study
This study
This study
Promega
This study
This study

F– 80lacZ M15 (lacZYA-argF)U169 recA1
endA1 hsdR17 (rk–, mk+) phoA supE44 thi-1 gyrA96
relA1 –
DH5α containing pCjaAB operon
DH5α containing pTig
DH5α containing pCbrR
DH5α containing pGEM-T Easy plus Cj1583c::cm
Conjugation helper strain, DH5α containing plasmid
RK2013

Invitrogen

E.coli
DH5α
JL690
JL691
JL652
JL692
JL48
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This study
This study
This study
This study
(Akiba et al. 2006)

Table 19. Key primers used for PCR in this study (Chapter V)
Primer

DNA Sequence (5’-3’)a

Product
size
(kb)

Target gene or
functional
description

Tf-F
Tf-R

TCATGAATTTCACCACTTAGCA
TGCTATCATTGAAGGCAAATTTTA

1.6

Trigger factor (tig)

CjaAB-F
CjaAB-R

TCGCCTAATGCCAAAGTTTC
TCACCATCTGCATTGCATTTA

2,7

Complete cjaAB

Cj0643-F
Cj0643-R

GCAATGCGTATCAACAATCC
AAAAATTTCCTTTCTTTTGAAAAC

1.5

cbrR

Cj1583c-F AAAAAGCCGAGGATTTGCTT
Cj1583c-R CTGTGGCTATAGCATGAACGA

2,0

Cj1583c

CmF
CmR

CGATTTAAATGCTCGGCGGTGTTCCTTT
CGATTTAAATGCGCCCTTTAGTTCCTAAAG

0.8

cmr cassette

Sap4-F
Sap4-R

GTG CTA AAA CGCTTA GTTTTTAGTATT
AATCAAATGCTCTAAACGATTTAA AAA

0.6

Conserved sapB

Sap5-F
Sap5-R

GATGCAGTG ATTAATCTTGTATTT TCAGG
TCCATTTTACAAATTTATAAGGACCTG

0.5

Conserved sapA
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Table 20. Susceptibilities of diverse Campylobacter spp. to F-1
Species
0.5
C. jejuni
C. coli

0
1

Number of isolates with MIC of F-1 (µg/ml)
1
2
4
8
2
3

8
3

58
8

128

85
5

16

Total
174

1
0

154
20

Table 21. Mutants with increased sensitivity to F-1
Strains

MICs
of F-1
(μg/ml)

Insertion
site/ORF
size

JL28
JL602
JL599
JL601

8
4
4
4

N/A
101/1335
910/1245
258/1248

Cj number
NCTC11168

Cj0193c
Cj0643
Cj0981c
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Functions or description

Trigger factor (Tig)
Response regulator (CbrR)
Putative transporter (CjaB)

A

cj0980

cjaB

cj0983

cjaA

Kan
B

def

tig

clpP

folE

C

Kan

recN

cbrR

tatD

pbpC

cj0645

cj0653c

Kan
D
sapF

nouA

cj1580c

sapD

cj1581c

sapC

cj1582c

sapB

cj1583c

sapA

cj1584c

cj1585c

Cm

Figure 7. Genomic context of cjaB (A), tig (B), cbrR (C), and cj1583c (D). The locations
of various major primers used in this study are indicated by arrows. The location and
orientation of antibiotic resistance cassette are indicated below each candidate gene
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A
Survival (%)

50
40
30
20
10

Strains

45
40
35
30
25
20
15
10
5
0

B

C
50
WT
CbrR::kan
Tig::kan
CjaB::kan

Survival (%)

Survival (%)

0

40
30
20
10
0

JL241

S3B

Strains

Strains

Figure 8. Role of cbrR, tig, cjaB and sapB in F-1 resistance in different C. jejuni strains.
The F-1 was added to washed bacteria and incubated for 2 hrs at 42oC under
microaerophic condition. Survival values are relative to original inoculumn (details of
bacterial strains in Table 18). (A) Susceptibility of wild-type 81-176 (WT), its cbrR
(JL656), tig (JL658) and cjaB (JL657) derivative mutants, and their corresponding
complementation construct JL668, JL695, and JL694 respectively to F-1. (B) Effects of
mutations in cbrR, tig, and cjaB on the susceptibility of NCTC 11168 and S3B to F-1.
(C) Inactivation of SapB increased susceptibility of 81-176 and NCTC 11168 to F-1.
JL697 and JL706 are isogenic SapB mutants of 81-176 and NCTC 11168 respectively.
Each data represents the mean value obtained from two independent experiments with
triplicate measurements in each independent experiment.
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A

C

B

Figure 9. Inactivation of Tig, CjaB, and SapB reduced C. jejuni 81-176 colonization of
chickens. Three chicken groups (10 or 11 birds/group) were inoculated with a 1:1 mixture
of wild type 81-176 and its SapB isogenic mutant (A), CjaB isogenic mutant (B), or Tig
isogenic mutant (C). For each group, five to six birds were euthanized and the cecal
contents were collected and used for CFU enumeration at the indicated day
postinoculation (DPI). Each symbol indicates the log10 number of CFU/g of cecal
contents for a single chicken. The horizontal bars indicate the means of groups at the
indicated times. Details were described in Materials and Methods.
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Campylobacter, commonly found as a commensal organism in the digestive tracts
of a variety of wild and domestic animals, is a major causative agent of human bacterial
gastrointestinal diseases in developed countries worldwide (Ruiz-Palacios 2007). Poultry
are the major reservoir for human Campylobacter infections (Kassenborg et al. 2004).
Thus, reduction of Campylobacter load in poultry is significant to food safety and public
health. In particular, at the same time that prevalence of infection is increasing,
Campylobacter

has

become

increasingly

resistant

to

antibiotics,

including

fluoroquinolones and macrolides, the major drugs of choice for treating human
campylobacteriosis (Luo et al. 2005), which raises an urgent need for novel intervention
strategies to prevent and control Campylobacter colonization in poultry (Lin 2009).
Antimicrobial peptides (AMPs) including bacteriocins (BCNs) are major components of
host innate immune systems as well as a novel class of antibiotics to control food-borne
pathogens. Recently, several anti-Campylobacter BCNs and chicken host antimicrobial
peptide (AMPs) such as fowlicidin-1 have been proposed to control Campylobacter in
poultry (Stern et al. 2005; Svetoch et al. 2005; Stern et al. 2006; Xiao et al. 2006).
Resistance mechanisms of this pathogen to these AMPs are critical to understand,
however, largely unknown. In this dissertation research, resistance mechanisms of
Campylobacter to PM, BCNs, and fowlicidin-1 were studied comprehensively.
Polymyxin B (PM) has been successfully used as a model to study resistant
mechanisms of Gram-negative bacteria to host defense AMPs (Ernst et al. 2001; Finlay et
al. 2004). Inactivation of the genes responsible for PM resistance usually results in
increased susceptibility of bacteria to a variety of innate AMPs, leading to reduce
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virulence of the mutants in an animal model system (Ernst et al. 2001). Functional
genomic studies described in Chapter II successfully identified several genes involved in
PM resistance in Campylobacter. However, these identified genes did not contribute to
Campylobacter resistance to other AMPs such as anti-Campylobacter BCNs and chicken
host defense peptides (F-1, 2). Thus, PM is not an ideal surrogate to study Campylobacter
resistance to physiologically relevant AMPs.

Resistance to the promising anti-Campylobacter BCNs was comprehensively
examined in this dissertation research. Studies in Chapter III and IV demonstrated that
Campylobacter only developed low-level BCN resistance with low frequency in vitro and
in vivo. The acquired BCN resistance can be transferred at both inter- and intra-species
levels. However, BCN resistance is not stable in Campylobacter. Genomic examination
of two BCN resistant mutants using microarray, random transposon mutagenesis, and
other functional approaches, revealed that the multidrug efflux pump CmeABC
contributed to both intrinsic and acquired resistance to BCN (Chapter III). The findings
from these two chapters support the feasibility of BCN in controlling Campylobacter in
poultry at the production level, and provide key information for the development of
effective and sustainable BCNs against Campylobacter infections.
Campylobacter resistance to F-1, a representative for chicken endogenous AMPs
was examined in Chapter V. The study in this chapter revealed that Campylobacter spp
were highly sensitive to F-1 and it was very difficult for Campylobacter to develop
resistance to F-1 in vitro. Comprehensive examination using random transposon
mutagenesis, homolog blast search, and site-targeted mutagenesis identified four genes
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(cbrR, cjaB, tig, and cj1385c) involved in resistance to F-1. These genes were also
required for optimal colonization of Campylobacter in chickens. The findings from
Chapter V will not only help us to develop more sustainable peptide antibiotics but also
provide insights into the delicate host-pathogen interactions and reveal novel intervention
targets to control Campylobacter infections in humans and animal reservoirs. Together,
the findings from this dissertation have revealed uniqueness and complexity of AMP
resistance in Campylobacter.
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